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Chapter I - General introduction 
 
 
 
1.1 Skeletal muscle biology 
 
 
Skeletal muscle is a contractile tissue managing voluntary movement and 
involved in maintaining of body’s posture and temperature. The development 
of musculoskeletal apparatus is controlled by a complex system of extrinsic 
and intrinsic regulatory mechanisms, starting after gastrulation, with 
somitogenesis, and continuing throughout life. 
 
 
1.1.1 Embryonic myogenesis 
 
During embryogenesis, first skeletal muscle fibers of trunk and limbs originate 
from paraxial mesoderm-derived structures, called somites, and additional 
myofibers are generated by subsequent waves of muscle progenitor cells that 
differentiate in rostro-caudal and medio-lateral direction.  
Spatiotemporal somitogenesis represents the earliest morphogenetic event of 
embryonic development and proceeds through the following stages: periodicity 
and separation of somites, epithelialization, specification, and differentiation. 
Paraxial mesoderm produces somites at cyclic species-specific intervals by 
expression of “oscillating genes” involved directly or indirectly in Notch and 
Wnt signaling pathways, and by gradient of Wnt, FGF8 and retinoic acid (RA) 
providing a “wave” motion (Betzinger et al, 2012). 
Somites separation proceeds in cranio-caudal direction and epithelialization 
begins before their detachment from paraxial mesoderm by deposition of 
extracellular matrix, expression of adhesion proteins (i.e. N-cadherin) and 
organization of a basal lamina between somites themselves and adjacent 
structures such as neural tube, notochord, dorsal ectoderm and lateral 
mesoderm. 
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Although specification of somites into different structures along the antero-
posterior axis of embryo is defined at early stages of somitogenesis by fine 
regulation of Hox genes, differentiation of somitic compartments into 
sclerotome, dermatome and myotome depends by local signals from the 
tegumentary ectoderm, notochord, dorsal laminae and floor plate of neural tube 
(Musumeci et al, 2015). 
 
 
 
Fig. 1 - Schematic representation of somitogenesis. 
 
Initially, toward the caudal region of the paraxial mesoderm, gradient of Wnt 
and FGF8 maintains cells to undifferentiated mesenchymal state and controls 
cyclic expression of “oscillating genes”. When cells move to cranial part, 
periodic activity of Notch pathway stops and increasing levels of RA polarize 
somites in dorso-ventral direction (Hofmann et al, 2004). 
The most ventral compartment forms the mesenchymal sclerotome, containing 
precursors that will generate cartilage and bone. The dorsal epithelial 
compartment constitutes the dermomyotome, where myogenesis occurs. 
Lateral portions of dermomyotome constitute the myotome, whose cells 
separate, migrate and generate myoblasts. According to their distance from 
neural tube, myoblasts differentiate in different kind of myofibers: myoblasts 
closest to the neural tube produce epaxial and extensor muscles, whereas those 
in the most distant region from above structure are precursors of hypaxial and 
flexor muscles (Musumeci et al, 2015). 
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Myoblasts differentiation is orchestrated by expression of myogenic regulatory 
factors Myf5 and MyoD in response to extrinsic factors, such as Wnt1 and 
Wnt3, secreted from the dorsal neural tube, and Wnt4, Wnt6 and Wnt7, 
produced from the surface ectoderm. Sonic hedgehog (Shh), released from the 
notochord and floor plate of the neural tube, is also involved in cellular 
commitment in the somite, by down-regulation of Pax3/7 e subsequent 
increasing of Myf5 levels (Cossu et al, 1996; Dietrich et al, 1998). 
The formation of head musculature, instead, differs significantly from trunk 
and limbs muscles specification; it originates from the cranial paraxial 
mesoderm (CMP) and from lateral splanchnic mesoderm (SpM), and is 
strongly influenced by cranial neural crest cells. 
Furthermore, while most of myoblasts differentiate to originate muscles, some 
of them remain in undifferentiated state and surround mature myofibers. These 
undifferentiated cells become satellite cells (SCs), responsible for postnatal 
muscle growth and repair (Betzinger et al, 2012). 
 
 
1.1.2 Transcriptional regulation of myogenesis 
 
Overall, commitment and terminal differentiation of muscle cells undergo 
transcriptional control of four myogenic regulatory factors (MRFs): Myf5, 
MRF4 (also known as Myf6), MyoD and myogenin (MyoG). 
MRFs are transcription factors sharing homologous basic helix-loop-helix 
(bHLH) domain that is required for DNA binding and dimerization with E-
protein family. Both MRF monomer and MRF-E protein heterodimer bind E-
box consensus sequence CANNTG in the promoters of downstream muscle-
specific genes, leading to muscle cell differentiation (Heidt et al, 2007). 
Critical transcription factors of muscle cell determination are Myf5 and MyoD 
and their specific knockout completely abrogates skeletal muscle formation. 
Moreover, MyoG is essential for terminal differentiation, as well as MRF4, 
regulating fusion and fiber maintenance. In particular, MFR4 plays a dual role, 
since it is also expressed in undifferentiated proliferating cells as determination 
gene (Londhe et al, 2011). 
 
9 
 
1.1.3 Adult myogenesis stem cells 
 
Adult muscle growth and regeneration is guaranteed by Pax3/7-positive 
myogenic stem cells, named satellite cells (SCs), and located between basal 
lamina and sarcolemma of associated myofibers. These cells can both replicate 
themselves (self-renew) and, after activation trigger, escape from quiescent 
state and give rise proliferating myoblasts by re-entering cell cycle. 
Most of quiescent SCs are characterized by expression of both Pax3/7 and 
CD34 (also known as sialomucin, an anti-adhesive molecule that act to aid 
migration); all CD34-positive quiescent SCs show activity in Myf5 locus, 
suggesting they are committed to myogenic lineage (Beauchamp et al, 2000). 
 
 
 
 Fig. 2 - Muscle differentiation stages and temporal expression of their regulatory genes. 
 
Unlike myogenic precursor cells, quiescent SCs don’t express the transcription 
factor MyoD until they switch to proliferating state, becoming active. Co-
expression of MyoD, desmin and MyoG in SCs was observed to be associated 
with a subpopulation of committed SCs that are totally prone to differentiate 
(Smith et al, 1994; Rantanen et al,1995). 
Both Myf5 and MyoD then play a specific and distinct role in SCs biology and 
adult myogenesis compared to that performed during embryonic development. 
Indeed, MyoD is required for differentiation potential of SCs-derived skeletal 
myoblasts (Sabourin et al, 1999; Cornelison et al; 2000), whereas Myf5 
regulates their proliferation rate and homeostasis (Gayraud-Morel et al, 2007; 
Ustanina et al, 2007). 
After expression of MyoD, a hierarchical gene expression circuitry is activated 
and leads to irreversible and sequential cascade of events regulating myoblast 
fusion and differentiation (Penn et al, 2004; Berkes and Tapscott, 2005). 
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1.1.4 Myoblast fusion 
 
During postnatal life, fusion of myogenic precursors is required to allow the 
muscle growth and replacement, and regeneration of myofibers after injury. 
The fusion process consists of two main phases characterized by the alignment 
of the myoblasts into parallel arrays and membrane fusion following 
rearrangement of actin cytoskeleton at contact sites. First step of myoblast 
fusion (which is referred to as “primary fusion”) is required for the formation 
of nascent myofibers (or primary myotubes). In the second phase, the 
recruitment of mononucleated myogenic cells to the primary myotubes 
complete the myofiber growth and nuclear accretion by a secondary fusion 
wave (Rochlin et al, 2010; Abmayr and Pavlath, 2012). 
Several studies conducted on myoblast cell culture models have been allowed 
to identify an extensive array of cell signaling pathways playing a critical role 
in myoblast fusion: some of these are activate subsequently to recruitment and 
contact of cell-surface proteins between fusion partners; other are integral part 
of the myogenic differentiation program, but contributing equally to fusion 
process.  
 
 
1.1.5 Signaling mechanisms in myoblast fusion 
 
Primary myoblast fusion and sarcomere assembly are mediated by fine 
organization on the plasma membrane of integrins, caveolin and others cell-
surface receptors, such as neogenin. Integrins, whose subunit β1 is an essential  
component of myogenic cells, link extracellular matrix ligands to several 
intracellular proteins. Binding of integrins to external molecules, in particular, 
induces integrin clustering and the recruitment and autophosphorylation of the 
non-receptor protein tyrosine kinase FAK (Schwander et al, 2003; Schaller, 
2010). Signaling triggered by FAK affects molecules involved in regulation of 
actin cytoskeleton, focal adhesion, mitogen-activated protein kinase (MAPK), 
and insulin signaling pathway (Quach et al, 2009). As consequence of FAK 
phosphorylation, which recruitment is orchestrated by protein kinase c (PKC) 
isoform PKCθ, the levels of caveolin-3 and β1D-integrin increase, enhancing 
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the extent of myoblast fusion (Madaro et al, 2011). Other components that 
promote fusion by interaction with FAK are neogenin and its ligands, the 
netrins. Specifically, Netrin2 determines FAK activation in a neogenin-
dependent manner in cultured primary myoblasts (Bae et al, 2009). 
 
 
  
    Fig. 3 - Signaling pathways involved in myoblast fusion. 
 
Rho family of guanosine triphosphatase (GTPase) plays a role in cytoskeletal 
re-organization through modulating activity of several downstream kinases and 
transcription factors. 
Time-dependent activation of RhoA protein is required for the induction of 
skeletal myogenesis in response to serum deprivation (Wei et al, 1998), but it 
necessitate to be deactivate before fusion occurs. RhoA inhibition during early 
stages of differentiation is mediated by RhoE (Fortier et al, 2008) and Rho 
GTPase-activating protein GRAF1 (GTPase regulator associated with focal 
adhesion kinase-1) (Doherty et al, 2011). RhoA activity, indeed, reduces 
stability and alters localization of M-cadherin, a cell adhesion molecule that is 
fundamental for myoblast fusion (Charrasse et al, 2006). 
In contrast to RhoA inhibitory role, other GTPases, such as Rac GTPases, 
positively regulate fusion process along its stages, governing activity of c-Jun 
N-terminal kinases (JNKs), serum response factor (SRF) and p38 MAPK 
(Meriane et al, 2000; Charrasse et al, 2002; Bryan et al, 2005). 
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Involvement in muscle differentiation of well-characterized subfamilies of 
MAPK (such as p38, ERK1/2, ERK5 and JNK) and of transforming growth 
factor beta (TGFβ)-activated kinase-1 is supported by several studies 
conducted on different myoblast cell models (Gredinger et al, 1998; Wu et al, 
2000; Mariane et al, 2000; Jones et al, 2001; Bhatnagar et al, 2010). The p38γ 
isoform is expressed preferentially in muscle tissue and it increases during 
differentiation (Lechner et al, 1996; Li et al, 1996). It stimulates the activation 
of MyoD and MEF2C, and synergistically increases the trans-activation 
potential of MyoD (Cuenda and Cohen, 1999). Expression of caveolin-3, a 
protein localized to the sarcolemma where it gives rise to complex with 
dystrophin, G-protein, Src-like kinases and other glycoproteins (Song et al, 
1996), requires p38 activation (Galbiati et al, 1999). Disruption of caveolin-3-
associated complexes has been observed in autosomal dominant limb girdle 
muscular dystrophy (LGMD), suggesting the importance of caveolins in the 
pathogenesis of muscular dystrophy (Minetti et al, 1998). In this regard, 
MAPK play a pivotal role in myotube survival and maintenance of 
differentiated condition.  
On the other hand, p38 intervenes also in the TAK-1/p38/nNFkB inhibitor 
signaling of myoblast differentiation (Trendelenburg et al, 2012), and ERK1/2 
appears strongly required for myoblast proliferation, but dispensable in 
promoting of muscle-specific gene expression and cell fusion (Jones et al, 
2001). In contrast, ERK5 drives myoblast differentiation through activation of 
transcription factors SP1 (specificity protein 1) which, in turn, promotes 
expression of transcription factors Klf2/4 (Kruppel-like factor 2/4) and 
nephronectin (Npnt), an extracellular matrix protein involved in cell-matrix 
adhesion (Sunadome et al, 2011). 
The outcome of fusion process into multinucleated myotubes is also regulated 
by calcium-dependent signaling covering several downstream targets including 
NFAT transcription factor family (Horsley et al, 2002, 2003; Wu et al, 2007). 
In particular, calcineurin-mediated NFATc2 activation plays a critical role in 
secondary myoblast fusion, regulation of muscle mass and myofibers diameter 
by increasing of interleukin-4 (Horsley et al, 2003) and MyoF (Demonbreun et 
al, 2010). 
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In adult myogenesis, NF-kB family proteins play an ambivalent role. In fact, 
activation of NF-kB occurs through canonical and non-canonical signaling 
pathways (Hayden and Grosh, 2004), that mediate inhibition (Li and Kumar, 
2008; Bakkar et al, 2008) or promote muscle differentiation (Enwere et al, 
2012) respectively. 
Wnt signaling pathway, as well as it is involved in embryonic differentiation, is 
equally crucial for myoblast fusion in adulthood. Specifically, inhibition of 
GSK-3β, a component of classical Wnt signaling network, enhances nuclear 
accumulation of β-catenin and promotes insulin-induced muscle differentiation 
(Rochat et al, 2004; von Maltzahn et al, 2012). Similarly, myoblast fusion is 
stimulated and accelerated by Wnt1 and Wnt3a ligands (Rochat et al, 2004; 
Pansters et al, 2011). In contrast, non-canonical Wnt pathway, that is activated 
in response to muscle injury in Sulf1/2 knockdown muscle models, inhibits 
fusion of skeletal progenitor cells by Wnt7a-mediated delocalization of FAK 
(Tran et al, 2012). An antagonist function is also played by canonical TGF-β 
signaling pathway, that, through activation of SMAD4, inhibits both myoblast 
proliferation and differentiation (Olson et al, 1986). 
 
 
1.1.6 Mediators of muscular atrophy and hypertrophy 
 
Muscle mass is controlled by the fine balance of anabolic (leading to protein 
synthesis and hypertrophy) and catabolic (enhancing protein degradation and 
inducing atrophy) processes (Mitch and Goldberg, 1996; Hasselgren, 1999; 
Jagoe and Goldberg, 2001). Increasing of muscle size and hypertrophy depends 
on insulin-like growth factor-1 (IGF-1) that mediates activation of PI3K/AKT 
pathway, resulting in phosphorylation of the FOXO proteins. 
AKT-mediated phosphorylation of transcription factor family FOXO prevents 
its translocation into the nucleus, hence the beginning of atrophy program 
(Brunet et al, 1999). Additionally, hypertrophy elicits activation of p70 and 
PHAS-1, two downstream effectors of mTOR signaling pathway involved in 
protein synthesis (Rommel et al, 2001; Reynolds et al, 2002). 
During atrophy, instead, there is an increase of ubiquitin ligases MAFbx 
(muscle atrophy F box, also called atrogin-1) and MuRF1 (muscle RING finger 
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1) expression, ubiquitin-protein conjugates and ubiquitin degradation pathway 
activity (Hasselgren, 1999; Bodine et al, 2001b; Gomes et al, 2001). 
Also myostatin (a TGF-β family member) signaling pathway plays a critical 
role as negative regulator of muscle mass and in regulating of skeletal fiber 
homeostasis, preventing myogenic program. Its antagonist, follistatin, as part 
of inhibin-activin-follistatin axis, has been shown to prevent muscle atrophy, 
enhancing muscle growth and strength. 
 
 
1.1.7 mTOR signaling pathway in muscle differentiation 
 
Mammalian target of rapamycin (mTOR) is involved in control of several 
cellular processes, such as cell growth, proliferation, differentiation, survival, 
autophagy and metabolism (Laplante and Sabatini, 2012). It forms two distinct 
complexes, mTORC1, mainly composed by GβL (or MLST8) and RAPTOR, 
and mTORC2, defined by presence of GβL and RICTOR. The rapamycin-
sensitive complex mTORC1 has two well-documented substrates involved in 
protein synthesis: S6K1 and 4E-BP1 (eIF4E-binding protein 1) (Ma and 
Blenis, 2009). Moreover, mTORC1 integrates signals from growth factor and 
other stressors regulating cell growth by mediation of TSC1/TSC2 complex, 
acting as GTPase-activating protein for Rheb (Manning and Cantley, 2003). 
On the other hand, the rapamycin-insensitive mTORC2 activity provides 
phosphorylation of AKT, PKCα and other kinases regulating cell survival, 
actin cytoskeleton organization and, in particular, myogenesis (Ge and Chen, 
2012). 
Preferentially through mTORC2, mTOR intervenes in primary and secondary 
myoblast fusion, and fiber maturation, in a kinase-independent and kinase-
dependent manners, respectively. Key mediator of kinase-independent pathway 
is IGF2, which triggers signaling cascade along the IRS1/PI3K/AKT axis. 
Furthermore, mTOR has been shown to suppress negative regulation of YY1 
on IGF2/AKT signaling components (Blatter et al, 2012). 
Kinase-dependent pathway under control of mTOR is necessary for secondary 
myocyte fusion and maturation of nascent myofibers. It starts with direct 
regulation by mTOR of MyoD and the subsequent activation of miR-1, which 
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suppresses HDAC4 and stabilizes MyoD itself, mediating over-expression of 
follistatin. Because of this, it has been hypothesized that mTOR might also 
manage many MyoD-regulated myogenic programs, in addition to evidences of 
a link between mTOR pathway and miRNAs involved in muscle differentiation 
(Sun et al, 2010). 
 
 
 
    Fig. 4 - mTOR signaling pathway. 
 
A positive role of mTOR during myogenesis is attributable to mTORC2 and its 
obligate component RICTOR, whereas mTORC1 acts a suppressive function, 
shifting the balance toward proliferation. Indeed, RAPTOR inhibits myoblast 
fusion by destabilization of IRS1 and consequent suppression of PI3K/AKT 
signaling (Ge et al, 2011). Also Rheb perturbs IRS1 protein, whereas S6K1 
mediates inhibition of RICTOR (Dibble et al, 2009; Julien et al, 2010; Ge et al, 
2011). 
Myogenic mTOR signaling intersects numerous pathways, some of which have 
been reported to directly or indirectly contrast with its activity. For example, 
FoxO1 induces degradation of mTORC2 components via proteasome, but is 
inhibited by AKT (Wu et al, 2008). Myostatin, that has been seen to negatively 
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regulate myoblast fusion, suppresses both AKT and MyoD in a SMAD2/3-
dependent manner (Langley et al, 2002; Trendelenburg et al, 2009).  
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1.2 Noncoding RNAs 
 
 
The noncoding RNAs (ncRNAs) fall within the major group of mammalian 
RNAs, accomplishing a remarkable number of biological functions. Indeed, 
they mediate DNA synthesis or genome rearrangement; participate to 
regulation of gene expression, intervening at the level of transcription, RNA 
maturation and translation; most of them operate as RNA-protein complexes 
(Cech and Steitz, 2014). In the last years, some classes of noncoding RNAs, 
such as long noncoding RNAs (lncRNAs) and microRNAs (miRNAs), have 
gained widespread attention as a potentially crucial layer of regulations 
implicated in several developmental processes and diseases, although the 
knowledge of their finely regulated expression and processing, and their 
mechanisms of action is still surprisingly limited. 
 
 
1.2.1 Long noncoding RNAs 
 
By definition, lncRNAs are non-protein coding transcripts longer than 200 nt. 
Their classification can be dealt with according to genomic context or a 
functional perspective, keeping always in mind that the current categorization, 
on the basis of these parameters, is considered to be mutually nonexclusive. 
LncRNAs may be transcribed as stand-alone units, which often referred to as 
lincRNAs for large intergenic (or intervening) noncoding RNAs (Guttman et 
al, 2009; Cabili et al, 2011; Ulitsky et al, 2011); or alternately transcribed from 
enhancers (eRNAs) (Kim et al, 2010; Wang et al, 2011a), promoters (TSSa-
RNAs, uaRNAs, pasRNAs and PROMPTs) (Core et al, 2008; He et al, 2008; 
Seila et al, 2008; Kanhere et al, 2010) or introns (Louro et al,2009; Rearick et 
al, 2011). 
Moreover, many lncRNAs have been identified as pseudogenic. Pseudogenes 
are evolutionarily “dead” genes due to nonsense, frameshift or other mutational 
events (Balakirev and Ayala, 2003; Pink et al, 2011). Transcribed pseudogenes 
were found to have acquired a new function and to regulate gene expression by 
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epigenetic or post-transcriptional mechanisms. In example, Xist transcript is 
hypothesized to be derived from pseudogenization, following the integration of 
several transposon-derived repeat elements, of the Lnx3 protein coding gene 
(Duret et al, 2006; Elisaphenko et al, 2008). 
In a strictly functional point of view, lncRNAs are involved in epigenetics, as 
recruiters, tethers and scaffolds; in both transcriptional and post-transcriptional 
regulation, and in the organization of nuclear compartments. 
 
 
 
   Fig. 5 - Mechanisms of lncRNA function. 
 
As regulators of chromatin states, lncRNAs have the ability to interact with 
chromatin-modifying complexes, such as PRC2 (Khalil et al, 2009; Kanhere et 
al, 2010; Zhao et al, 2010). In fact, Polycomb complexes, including several 
factors that bind or modify chromatin marks, have been seen to be recruited to 
specific genomic loci in mammals by lncRNAs, such as HOTAIR (Rinn et 
al,2007), Kcnq1ot1 (Pandey et al, 2008) and ANRIL (Yap et al, 2010; Kotake 
et al, 2011). 
Furthermore, lncRNAs can directly affect the process of transcription, acting as 
transcriptional co-regulators, such as SRA, a co-activator for a number of 
nuclear steroid receptors (Lanz et al, 1999, 2002); or acting as decoys for 
transcriptional factors, such as PANDA and NRON lncRNAs (Willingham et 
al, 2005; Hung et al, 2011) or inhibitors of polymerase II activity, such as 
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lncRNAs produced from SINEs (Espinoza et al, 2004; Mariner et al, 2008) or 
from DHFR promoter (Schnell et al, 2004). 
In post-transcriptional regulation, lncRNAs mediate mRNA processing or 
influence its stability and translation efficiency. 
MALAT1 has been found to affect alternative splicing; analogously, 
Gomafu/MIAT lncRNA may hide spliceosome formation, altering splicing of a 
subset of messengers (Sone et al, 2007; Tsuiji et al, 2011). Moreover, 
MALAT1, as well as NEAT2, has been shown to localize splicing factors to 
nuclear compartments called speckles (Bernard et al, 2010), suggesting that 
lncRNAs are simultaneously regulators of nuclear organization. Both Xist and 
Kcnq1ot1 have been also observed to target their interactors to perinucleolar 
compartment to maintain silencing (Zhang et al, 2007; Pandey et al, 2008). 
Interestingly, lncRNAs are emerging as both sources and sinks of small RNAs. 
Rather than competing for miRNA-binding sites, lncRNAs can compete for the 
miRNAs themselves. Several mammalian pseudogenes-derived lncRNAs, such 
as PTEN1 and KRASP1, have miRNA-binding sites in their 3’-UTR, acting as 
sponges to sequester miRNAs away from their targets (Poliseno et al, 2010). 
On the other hand, lncRNAs can themselves generate miRNAs and other small 
RNA species, such as H19, that hosts miR-675 (Cai and Cullen, 2007; Keniry 
et al, 2012), or GTL2, anti-RTL1 and Mirg lncRNAs, that give rise up to 50 
miRNAs and at least 40 snoRNAs (da Rocha et al, 2008). 
 
 
1.2.2 Natural antisense transcripts 
 
Around 70% of annotated sense transcriptional units have reported antisense 
counterparts. Natural antisense transcripts (NATs) are considered a subgroup 
of lncRNAs that is poorly conserved among species (Johnsson et al, 2014). 
Generally, they affect their partner coding genes by suppression or activation, 
or act in stabilization of long-range chromosomal interactions. One of the well-
documented sense antisense (SAS) pairs is Xist/Tsix, involved in control of X 
chromosome inactivation (Lee et al, 1999a). Moreover, other SAS pairs have 
been reported in imprinted region, such as Kcnq1/Kcnq1ot1 (Kanduri et al, 
2006) and Igf2r/Air (Lyle et al, 2000). 
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NATs can be spliced, polyadenylated or not-polyadenilated, and have been 
classified basing on their relative localization to coding gene sequences: head-
to-head, tail-to-tail and fully overlapping. Often, NATs have been reported as 
physically discrete transcriptional units, very close to sense coding gene, and 
are referred to as in nearby head-to-head and nearby tail-to-tail orientations 
(Osato et al, 2007). 
 
 
 
            Fig. 6 - Transcriptional orientation of NATs. 
 
For most of NATs, as well as other lncRNAs, biological functions proposed 
contemplate modulation of mRNA stability and decoy, scaffolding and 
tethering mechanisms. Recently has been suggested that NATs may serve as 
precursor for endogenous siRNA and miRNA generation. This hypothesis is 
supported by the importance of SAS duplex in siRNA biogenesis and by 
evidence of interaction between NATs and argonaute (AGO) family proteins 
(Polikepahad and Corry, 2013; Werner et al, 2014). 
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1.2.3 MicroRNAs 
 
MicroRNAs (miRNAs or miRs) are small RNAs of 21-25 nucleotide in length, 
produced by two RNase III proteins, DROSHA and DICER, and able to 
negatively regulate the gene expression at post-transcriptional level (silencing), 
mediating the mRNA degradation or inhibiting its translation.  
MicroRNA-coding genes are transcribed by RNA polymerase II as primary 
miRNA (pri-miRNA), typically long over 1 kb and containing local stem-loop 
structures that undergoes several step of maturation. Its processing begins in 
the nucleus by action of Microprocessor complex, of which the core elements 
are the nuclear RNase III DROSHA and its essential co-factor DGCR8. 
The pri-miRNA stem-loop recognition is operated by the two double strand 
RNA binding domains (dsRBDs) of DGCR8, whereas its C-terminus interacts 
with DROSHA, recruiting it to the pri-miRNA cutting site.  
DROSHA cleaves the hairpin approximately 11 bp away from the “basal” 
junction between the single strand RNA and dsRNA of the stem-loop, and 22 
bp away from the “apical” junction linked to the terminal loop (Zeng et al, 
2005; Han et al, 2006). DROSHA’s cleavage generates a short dsRNA (~65 nt) 
called pre-miRNA, which is exported to cytoplasm, where maturation can be 
completed. Transferring of pre-miRNA from nucleus to cytoplasm is mediated 
by RAN-GTP/exportin 5 (EXP5) complex; hydrolysis of GTP bonded to 
nuclear protein RAN results in disassembly of the complex and in the release 
of pre-miRNA into the cytosol. Here the pre-miRNA is processed by DICER, 
an RNase III endonuclease recognizing the 3’ overhangs leaved by DROSHA. 
DICER’s processing generates a small RNA duplex (miRNA:miRNA*) that is 
subsequently loaded onto AGO protein in the RNA-induced silencing complex 
(RISC) (Hammond et al, 2001; Mourelatos et al, 2002). 
After loading into RISC, RNA duplex is unwound and the strand selection 
occurs. As strand selection is not completely strict, the more instable strand can 
be retained with varying frequency. Moreover, the less abundant passenger 
strand (miRNA*) is active in silencing, albeit usually less potently than the 
more abundant guide strand (miRNA). Alternative strand selection (also known 
as arm switching) has been observed comparing miRNA isoforms (Chiang et 
al, 2010). 
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            Fig. 7 - Canonical pathway of miRNA biogenesis. 
 
That described above is considered the canonical miRNA biogenesis pathway. 
However, various alternative mechanisms generating miRNAs or miRNA-like 
short RNAs have been observed. For example, small RNA precursors may be 
generated through mRNA splicing in a DROSHA-independent manner (Flynt 
et al, 2010); analogously, miRNAs may also be produced by a DICER-
independent AGO2-mediated (Cheloufi et al, 2010; Yang et al, 2010) or by 
terminal uridylyl transferase (TUTase)-dependent DICER-mediated cleavage 
(Heo et al, 2012). 
Control of gene expression attended to by mature miRNAs happens at 
posttranscriptional level, mainly by messenger degradation or translation 
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inhibition. Generally, interaction between miRNA and mRNA is based on 
complementarity of a 6-8 nt sequence known as seed (Zynoviev et al, 2010). 
The seed sequence complementarity and its length establish the specificity of 
action and the repression strength of miRNA, respectively, although several 
evidences demonstrate the possibility of nonseed-dependent target recognition 
(Brodersen et al, 2009). 
Commonly, miRNAs regulate their target by binding to 3’UTR. Multiple 
binding sites for the same miRNA in 3’UTR strongly enhance mRNA 
suppression. Overall, miRNA binding sites were found also in 5’UTR and 
coding region; interestingly, genes containing miRNA binding sites in both 
coding sequence and 3’UTR are more significantly regulated than those 
targeted in 3’UTR only (Fang and Rajewsky, 2011). 
 
 
1.2.4 LncRNAs and miRNAs in muscle differentiation 
 
As lncRNAs have emerged to be able to regulate gene expression at various 
levels, demonstrating to be a class of functionally versatile transcripts, they 
have been studied in relation to development, cell identity maintenance and 
differentiation. In the last few years, as expected, lncRNAs appeared to play a 
crucial role also in skeletal myogenesis. 
Two members (CE and DRR) of a group of lncRNAs called enhancer-derived 
RNAs (eRNAs), originating upstream the regulatory region of MyoD, 
modulate muscle differentiation by directing chromatin-remodeling events to 
promote expression of MyoD and MyoG. Another lncRNA, Yams (YY1-
associated muscle lincRNAs), recently identified, displays function of 
transcriptional activator (Lu et al, 2013), as well as SRA, that besides 
functioning as scaffold, forms complex with MyoD and p68/p72, acting as co-
activator of transcription of a subset of MyoD target genes (Caretti et al, 2006). 
Fascinatingly, MALAT1 has been revealed as downstream target of myostatin 
(Watts et al, 2013), suggesting a role in control of muscle mass and atrophy. 
Also H19 works at different levels: binding Polycomb complex, it mediates 
Igf2 repression (Ripoche et al, 1997); containing several binding sites for let-7 
microRNA family, it may act as RNA sponge (Kallen et al, 2013). Moreover, 
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H19 exon 1 encodes miR-675-5p and miR-675-3p (Cai and Cullen, 2007), that 
targeting SMAD1, SMAD5 and Cdc6, play an important role in skeletal 
muscle differentiation and regeneration (Dey et al, 2014). 
Linc-MD1, strongly reduced in Duchenne dystrophy, acts as sponge of miR-
133 and miR-135 to regulate expression of MAML1 and MEF2C. Its up-
regulation mediates anticipation of myogenesis program (Cesana et al, 2011). 
The boundary between lncRNAs and miRNAs results to be particularly labile. 
Indeed, a newly discovered noncoding transcript (lnc-31) overlapping coding 
region of miR-31 has been shown to counteract differentiation (Ballarino et al, 
2015), as well as miR-31 controls proliferation by regulating of Myf5 (Crist et 
al, 2012) and dystrophin (Cacchiarelli et al, 2011). 
Unlike lncRNAs, miRNAs involved in skeletal muscle differentiation are much 
more characterized. In muscle cells, SRF and MEF2 family transcription 
factors cooperate with MyoD and MyoG to activate muscle-specific miRNAs 
(myomiRs): miR-1-1 and miR-133a-2 (clustered on chromosome 20), miR-1-2 
and miR-133a-1 (clustered on chromosome 18) and miR-206 and miR-133b 
(clustered on chromosome 6) (Goljanek et al, 2012). As miR-133 is involved in 
proliferation maintenance, miR-1 and miR-206 increase during myogenesis 
(Cacchiarelli et al, 2010) and promote differentiation, blocking several genes 
such as Pax3 (Goljanek et al, 2011) and Notch3 (Gagan et al, 2012). 
Several other nonmuscle-specific miRNAs are equally involved in myoblast 
expansion and fiber maturation: miR-489 rapidly decrease after SCs activation, 
making Dek able to promote proliferation; miR-22, miR-34, miR-145, miR-
365 and miR-486 are instead induced during differentiation (Marzi et al, 2012). 
In particular, miR-486 regulates Pax7 and atrophy-related genes, such as PTEN 
and FoxO1 (Alexander et al, 2011), preserving muscle mass reduction, as well 
as miR-23a, which suppresses both MAFbx/atrogin-1 and MuRF1 (Wada et al, 
2011), and has been predicted to target myostatin and YY1 (Lin et al, 2009). 
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1.3 Facioscapulohumeral dystrophy 
 
 
 
1.3.1 Clinical characteristics 
 
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common 
autosomal dominant muscular dystrophy after dystrophinopathies and 
myotonic dystrophy, affecting approximately 1 in 15,000 individuals 
worldwide (Flanigan et al, 2001). 
Clinical symptoms usually appear during the second decade and are mainly 
characterized by asymmetrical and progressive muscle weakness and atrophy, 
initially of the facial, scapular and humeral muscles, involving the abdominal 
muscles and the musculature of the lower limbs and feet in the late stages of 
disease. Deltoids remain minimally affected, whereas biceps and triceps are 
particularly involved, resulting in sparing of the forearm musculature 
(Lemmers et al, 2014). 
Several non-muscle tissues are also frequently affected in FSHD; indeed, an 
high frequency in hearing loss (75%) and retinal telangiectasia (60%) has been 
reported (Brouwer et al, 1991; Padberg et al, 1995). Central nervous system 
defects may also occur, with learning difficulties and epilepsy, particularly 
evident in some severely affected individuals (Di Lazzaro et al, 2004). Other, 
less frequent clinical manifestations include respiratory insufficiency and 
cardiac conduction alterations (Kilmer et al, 1995; Galetta et al, 2005; Trevisan 
et al, 2006). 
 
 
1.3.2 Genotype-phenotype correlations 
 
Genotype-phenotype association studies on FSHD affected patients have 
highlighted two clinical forms of FSH muscular dystrophies (which are 
referred to as type I and type II respectively) that are indistinguishable from a 
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symptomatological point of view, although they are linked with two markedly 
different genotypes. 
FSHD type I (also called FSHMD1A) represents more than 95% of clinical 
cases and is associated with the contraction of tandemly repeated 3.3 kb units 
of the D4Z4 macrosatellite at the subtelomeric q35 region on chromosome 4 
(4q35). In normal individuals, the array varies between 11 and 110 units, 
whereas FSHD type I affected subjects carry a contraction to 1-10 repeats. 
Besides that at least one macrosatellite unit is required to develop FSHD, the 
degree of D4Z4 contraction would seem to correlate with disease severity and a 
more rapid progression of musculature involvement (Bindoff et al, 2006; 
Hobson-Webb and Caress, 2006; Klinge et al, 2006).  
FSHD type II, instead, is characterized by normal-sized D4Z4 repeat array and 
reported linked to mutation in SMCHD1 gene, on chromosome 18, encoding a 
protein containing a hinge domain involved in the structural maintenance of 
chromatin in a more heterochromatic state. Loss of function mutation leads to 
decreasing of the levels of SMCHD1 protein and, subsequently, to 
hypomethylation of D4Z4 macrosatellite (Lemmers et al, 2012). An 
euchromatic-like D4Z4 repeat array represents the only common feature 
between FSHD type I and II. 
 
 
1.3.3 Penetrance and anticipation 
 
Penetrance of FSHD depends on age and gender, resulting in 83% for 30 years 
old individuals and significantly greater for males (95%) than females (69%) 
(Zatz et al, 1998; Tonini et al, 2004). Gender differences in penetrance remain 
poorly understood; analogously, putative mechanism for anticipation is still 
controversial. Originally suggested by Zatz and colleagues, on observation of 
multigenerational families, anticipation phenomenon in FSHD appears to have 
been subsequently excluded by more extensive epidemiologic studies (Flanigan 
et al, 2001).  
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1.3.4 Molecular basis of FSHD 
 
Over the years, FSHD has been proved to be a genetically heterogeneous 
disorder involving both genetic and epigenetic alterations. A detailed genomic 
characterization of 4q35 region revealed existence of three 4q subtelomere 
alleles (named A, B and C), fifteen single nucleotide polymorphisms (SNPs) in 
D4F104S1 (p13E-11) region, and ten simple sequence length polymorphism 
(SSLP) variants localized 3.5 kb proximal to D4Z4 repeat array. Considering 
these features, 4q alleles was grouped in eighteen haplotypes (Lemmers et al, 
2010a). The 4qA allele differs from the other two by the presence of a 6.2 kb β-
satellite sequence (van Geel et al, 2002). FSHD is exclusively associated with 
4qA variant (Lemmers et al, 2002; Thomas et al, 2007); furthermore, D4Z4 
contraction gives rise to dystrophic phenotype only in three specific haplotype 
backgrounds: 4qA159, 4qA161 and 4qA168 (Lemmers et al, 2007, 2010b).  
 
 
 
     Fig. 8 - Summary of genetic and epigenetic characteristics of 4q35 locus.  
 
However, these haplotypes represent only a permissive condition and by 
themselves are not sufficient to cause FSHD; indeed, 4qA161 healthy or 
asymptomatic carriers have been reported (Arashiro et al, 2009). 
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Further analysis of permissive and non-permissive haplotypes has identified a 
variant C/T SNP within pLAM sequence, localized distal of D4Z4 array. The 
SNP can create a consensus polyadenylation signal ATTAAA, found in most 
FSHD patients. Polyadenylation signal has been observed to be involved in 
expression of stable DUX4 mRNA. DUX4 open reading frame (ORF) was 
found to be enclosed within each D4Z4 unit, but it has been hypothesized that 
its transcription initiates only from the last repeat and proceeds along the distal 
pLAM region, which provides both an intron and a functional polyadenylation 
signal, stabilizing the transcript and guaranteeing its translation (Dixit et al, 
2007). 
Since DUX4 protein was initially detected in FSHD primary muscle cells and 
only in permissive haplotypes, its expression was considered a consequence of 
D4Z4 contraction and DUX4 itself became the first gene involved in FSHD 
etiopathogenesis (Dixit et al, 2007; Bosnakovski et al, 2008; van der Mareel et 
al, 2011; Tassin et al, 2013). Nevertheless, recent work reported DUX4 also in 
healthy individuals, taking back expression of this gene in the area of necessary 
but not sufficient conditions for development of the disease (Jones et al, 2015). 
Other FSHD candidate genes localized upstream D4Z4, such as FRG1, FRG2 
and SLC24A4 (ANT1), are inappropriately over-expressed in affected muscle 
(Gabellini et al, 2006), but their role in both initiation and severity of disease is 
still controversial. Indeed, while initial reports suggested that FRG1 expression 
levels were elevated in patient muscle cells (Gabellini et al, 2002; Gabellini et 
al, 2006; van Koningsbruggen et al, 2007), later studies have found no 
alteration in its expression (Klooster et al, 2009; Arashiro et al, 2009; Masny et 
al, 2010). Analogously, several analysis of FSHD genetic profile have 
proposed a causative role for DUX4c, an homologous of DUX4 gene located 
outside D4Z4 macrosatellite, on chromosome 4 (Bosnakovski et al, 2008a; 
Ansseau et al, 2009). 
However, two FSHD patients were found with a 75 kb deletion that removed 
both FRG2 and DUX4c on the 4q35 pathogenic allele, suggesting that neither 
gene is directly responsible of FSHD (Deak et al, 2007). 
As mentioned, FSHD has gradually assumed the characteristics of epigenetic-
based pathology. Normally, the 4q35 locus is highly methylated, displaying 
features of unexpressed, strongly heterochromatic region (Jiang et al. 2003; 
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Yang et al. 2004). Conversely, hypomethylation of both contracted (in FSHD 
type I) and non-contracted (in FSHD type II) D4Z4 alleles has been reported 
(van Overveld et al. 2003, de Greef et al. 2007, 2009, 2010). The likelihood is 
that such epigenetic changes are disease-related and influence the functionality 
of 4qter region, most probably by the up-regulation of its associated genes 
(Saccone and Puri, 2010). 
 
 
1.3.5 DUX4 gene 
 
DUX4 protein was initially described as a double-homeodomain transcription 
factor (Gabriels et al, 1999) and therefore included within paired class 
homeodomain protein family, with a function similar to the skeletal muscle 
stem cell regulators Pax3 and Pax7. In that respect, and in order to explain 
skeletal myogenic phenotype in FSHD, a model based on DUX4 competition 
with Pax3/7 for target recognition has been recently proposed (Bosnakovski et 
al, 2008). However, although DUX4 homeobox sequences are very close to 
Pax3/7 homeodomain and both contain TAAT core motif, the DUX4 
consensus site shows two TAAT motifs in tandem, whereas Pax3/7 site have 
the same motif in head-to-head orientation (Zhang et al, 2016). 
Across D4Z4, each repeated DUX4 gene is composed by one exon terminating 
with a stop codon; conversely, DUX4 gene in the last repeat of D4Z4 sits next 
to a sequence polymorphisms harboring two additional untranslated exons, two 
small introns and a non-canonical polyadenylation signal (pLAM) required for 
stabilizing DUX4 mRNA. 
Intronless DUX4 mapping on first D4Z4 repeats contains two major ORFs: a 
135 aa ORF beginning with MER codon that has no homology with proteins 
deposited in Genbank database; and a 689 aa ORF beginning with MQGR 
codons, that include two other in-frame ORFs: one beginning with MKG codon 
and the other corresponding to canonical DUX4 ORF that begins with MAL 
codon. The last repeat shows sequence variations that extend MER ORF to 256 
aa and truncate MQGR after 241 aa (Snider et al, 2009). 
Canonical DUX4 mRNA starts upstream MAL ORF in the last D4Z4 unit and 
undergoes alternative splicing to generate isoforms: a full-length form (DUX4-
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fl) containing the two exons and the pLAM region; and a second transcript 
(DUX4-s) utilizing a cryptic splice donor site in the DUX4 ORF that maintains 
the N-terminal double-homeobox domains and removes the carboxyterminal 
end (Snider et al, 2010). 
DUX4-fl and DUX4-s are associated to toxic and non-toxic isoforms of DUX4, 
respectively (Geng et al, 2012; Mistuhashi et al, 2012). An alternative full-
length form (DUX4-fl2) characterized by retention of first intron and skipping 
of stop codon in the first exon has been observed (Dixit et al, 2007; Snider et 
al, 2009), but its function is still poorly understood. 
 
 
 
Fig. 9 - DUX4 gene inside D4Z4 last repeat. Schematic representation of DUX4 ORFs and its 
splicing isoforms. HOX = homeobox. PAS = polyadenylation signal. 
 
Because of the presence of homeodomains and the strong trans-activation 
property of C-terminus domains (Kawamura et al, 2006), DUX4 was presumed 
to act as transcription factor. Protein was initially detected into the nucleus by 
immunofluorescence and three nuclear localization sequences (NLSs) has been 
reported: NLS1 (RRRR23) and NLS2 (RRKR98), located at N-terminus portion 
of homeodomains 1 and 2; and NLS3 (RRAR148) at C-terminus of homeobox 2 
(Corona et al, 2013). The main target of transcriptional activatory role played 
by DUX4 is PITX1, a gene specifically up-regulated in FSHD patients (Dixit et 
al, 2007). However, recently DUX4 has been observed to alter proteostasis by 
interaction with ubiquitinated protein (Homma et al, 2015) and to translocate 
into cytoplasm where is involved in binding with a plethora of interactors, such 
as desmin, α-actinin, tubulin, C1QBP, FUS/TLS, SRSF9, SFPQ and RBM24 
(Anseau et al, 2016). 
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These evidences, in addition to recognition of DUX4-fl forms also in healthy 
subject (Jones et al, 2015), demonstrate that there are still unclear aspects about 
the physiopathological role of this protein. 
 
 
1.3.6 DUX4c 
 
DUX4c (centromeric or contracted) is a DUX4 homologue, mapping 42 kb 
proximal to the D4Z4 repeat array, next to FRG2 gene, on chromosome 4. 
DUX4c is a truncated and inverted D4Z4 unit (Wright et al, 1993) that shares 
with its homologous a large part of the coding and the proximal sequences 
(including the two homeoboxes). Indeed, DUX4c ORF extends over 1125 bp 
as compared to 1273 for DUX4, and both genes share a 1137 bp fragment 
starting 111 bp upstream their common start codon (MAL), except for three 
mismatch outside double homeobox domain (Ansseau et al, 2009). 
DUX4c is actively transcribed and translated, and was found up-regulated in 
FSHD myoblasts. Its characterization revealed that mRNA is polyadenylated, 
although no canonical polyadenylation signal was detected. Moreover, DUX4c 
has heterogeneous 3’end, whereas 5’RACE data suggests that transcription 
could be driven by both variant TATAA box and the several GC boxes found 
in the promoter region (Ansseau et al, 2009). 
DUX4c ORF encodes a 47 kDa protein, composed by 347 aa. DUX4c has been 
shown to regulate Myf5 (Ansseau et al, 2009) and to induce myomiR miR-1, 
miR-206, miR-133a and miR-133b (Dmitriev et al, 2013) by binding to their 
promoters. DUX4c is mainly localized into nucleus in proliferating myoblasts, 
whereas it moves to cytoplasm during myoblast fusion, interacting with several 
proteins, such as desmin, α-actinin and tubulin (with double homeobox 
domain), and C1QBP and RBM24 (with C-terminus domains) (Anseau et al, 
2016). This data suggested that DUX4c may disturb muscle differentiation, 
altering cytoskeleton organization and perturbing spliceosome complex. 
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1.3.7 DUX4-like genes 
 
D4Z4 (4q35.2) has an highly homologous polymorphic repeat array of similar 
size on subtelomeric region 10q26 (Wijmenga et al,1992; Bakker et al, 1995; 
Deidda et al, 1995). Indeed, both macrosatellites mapping on chromosomes 4 
and 10 are identically tandemly arranged and, in 4qA/10q alleles, followed by a 
6.2 kb of 68 bp β-satellite sequences repeated in tandem. 
 
 
 
Fig. 10 - Summary of DUX4-like genes and β-satellite sequences in the human genome. 
 
DUX4-like genes on 10q26 conserve their ORF, but the last unit lacks PAS in 
exon 3 and not produces stable transcripts in skeletal muscle cells (Lemmers et 
al, 2010). On the other hand, in human testis, a polyadenylated transcript from 
DUX4-like on 10q array was detected; here 3’RACE experiments confirmed 
the use of alternative PAS in exon 7, located approximately 6.5 kb distal to 
pLAM sequence (Snider et al, 2010). 
In addition to 10q26 homologous, first southern analysis and experiments of 
immunofluorescence in situ hybridization (FISH) by using D4Z4-containing 
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probes suggested the existence of many other sequences related to D4Z4 in the 
human genome (Wijmenga et al,1992; Hewitt et al, 1994; Winokur et al,1994). 
Further investigation on somatic cell hybrids initially confirmed the presence 
on the short arms of acrocentric chromosomes of a 3.3 kb repeat family, having 
a complex structure, partially similar to D4Z4 (Lyle et al, 1995). 
These repeat arrays on acrocentric chromosomes are characterized by a degree 
of heterogeneity due to the position of 68 bp satellite sequences interspersed 
between the 3.3 kb repeats (Meneveri et al, 1993) or to distribution of LSau 
sequences forming part of 3.3 kb repeat itself. However, no active homeobox 
sequence was found in these D4Z4-related repeat arrays, suggesting that the 
DUX4 ORF enclosed within 3.3 kb repeats on acrocentrics was disrupted by 
recombination or transposition events involving other repetitive elements, 
generating pseudogenes (Lyle et al, 1995). 
Tandemly repeated organization of interspersed DUX4-like/satellite sequences 
was observed also in heterochromatic regions on chromosome 1q12, 9q12, 
10cen and 18p11.32, with sequence identities ranging from 80-99% (Winokur 
et al, 1994, Giussani et al, 2012). 
On human chromosome 3p12.3 has been reported an inverted copy (which 
referred to as DUX4L26) of D4Z4 unit, upstream to FGR2 gene, probably 
derived from translocation of DUX4c and its proximal regions. Indeed, 
multiple sequence alignment confirmed sharing identity between DUX4L26 
and DUX4c, with putative introns interrupting the coding sequences (Zhang 
and Holland, 2011). 
Several intronless DUX4-like sequences were finally found on 12p11.1 
(DUX4L27), 20q11.1 (DUX4L32-34) and Yq11.21 (DUXY1-4), and having 
assorted degrees of homology with D4Z4 units. In particular, all four Y-
chromosomal DUX4-like copies are enframed by β-satellite blocks (in a similar 
configuration observed on acrocentrics) and lack the potential to encode the 
second homeodomain (Clapp et al, 2007). Furthermore, DUXY1 ORF shows a 
1 bp deletion giving rise to markedly different C-terminus, whereas in the 5’ of 
DUXY4 an Alu insertion was identified (Schmidt et al, 2009). 
The presence of an high number of DUX4-like sequences across the human 
genome suggests the complex evolutionary history of D4Z4 and its coding 
gene DUX4. 
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However, unlike FSHD-related DUX4 and DUX4c, transcriptional potential 
and biological function of other DUX4-like genes remain poorly understood, 
so much so that they are still considered pseudogenes or junk. 
 
 
1.3.8 DBE-T 
 
Every D4Z4 unit contains a motif identical to Drosophila PRE sequence 
(CNGCCATNDNND), overlapping the DBE (D4Z4 binding element) region, 
recognized by YY1, EZH2 and HMGB2, members of Polycomb protein group 
(PcG) (Myhaly et al, 1998; Gabellini et al, 2002; Bodega et al, 2009). DBE, as 
well as the remainder D4Z4, is a CG-rich region, and CpG islands are critical 
in PcG recruitment (Mendenhall et al, 2010; Neguembor and Gabellini, 2010). 
Recently, a lncRNA named DBE-T has been identified, starting from proximal 
region to D4Z4 macrosatellite, upstream of NDE (nondeleted element). DBE-T 
was detected as large as 9.8 kb, and it resulted chromatin-associated and over-
expressed in FSHD muscle cells versus control (Cabianca et al, 2012). 
DBE-T functions in cis by directly recruiting the Trithorax group (TrxG) 
protein Ash1L to 4q35.2 locus. Here Ash1L mediates the de-repression of 
FSHD locus and overexpression of DUX4, making DBE-T the first activatory 
lncRNA involved in a human genetic disease (Cabianca et al, 2012). 
 
 
1.3.9 Other noncoding transcripts from D4Z4 macrosatellite 
 
In addition to DBE-T, other lncRNAs have been recognized inside D4Z4 units, 
in healthy and FSHD muscle cells: three in sense and three in antisense to 
DUX4. Furthermore, several mi/siRNA-sized fragments has been observed to 
originate upstream DUX4 and within both its coding and intronic regions 
(Snider et al, 2009). Recently, a further study proposed a functional model of 
DUX4 sense/antisense transcript pairs as precursors of these D4Z4-derived 
mi/siRNA-sized fragments in a DICER-dependent manner. Researcher 
hypothesized that these small RNAs can epigenetically suppress DUX4 
through gene silencing mediated by AGO2 pathway (Lim et al, 2015). 
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Interestingly, D4Z4-derived cytoplasmic and/or chromatin/AGO2-associated 
short RNAs were found also in WI38 primary human fibroblasts and HeLa 
cells (Benhamed et al, 2012; Ameyar-Zazoua et al, 2012), and tested in turn for 
their ability to repress DUX4 itself (Lim et al, 2015). 
Although the mechanism of action of these transcripts and their involvement in 
FSHD is still largely unknown, all of these findings highlight the extreme 
complexity of the macrosatellite D4Z4. 
 
  
 
Fig. 11 - Schematic representation of lncRNAs and mi/siRNA-sized fragments crossing 
DUX4 in healthy and FSHD muscle cells. Numbers represent relative position to MAL start 
codon of DUX4 ORF. HOX = homeobox. PAS = polyadenylation signal. 
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Chapter II - Materials and Methods 
 
 
 
2.1 Cell lines 
 
Immortalized human muscle cell lines were obtained from Boston Biomedical 
Research Institute (BBRI, Senator Paul D. Wellstone Muscular Dystrophy 
Cooperative Research Center for FSHD). Cell lines used in this study have 
been derived from both biceps and deltoid biopsies of healthy and FSHD 
subjects. Details about cell strains and clinical characteristics of donors are 
shown below. 
 
 
  
 
 
 
Cells were cultured in 0.1% gelatin-coated tissue culture dishes (Corning) with 
growth LHCN medium (4:1 DMEM : medium 199; 15% FBS; 0.03 μg/ml zinc 
sulfate; 1.4 μg/ml vit. B12; 0.055 μg/ml dexamethasone; 0.8 mM sodium 
piruvate; 2.5 ng/ml HGF; 10 ng/ml bFGF; 1% Pen/Strep; 1% Amphotericin B; 
0.02 M HEPES), following BBRI’s guidelines. 
Differentiation was induced at 80-90% of confluence by replacing growth 
medium with fresh medium containing: 4:1 DMEM : medium 199; 2% horse 
serum (HS); 1 mM sodium piruvate; 2 mM L-glutamin; 1% Pen/Strep; 1% 
Amphotericin B; 0.02 M HEPES. We also used 10% KOSR in substitution of 
2% HS according to experimental requirements. 
We calculate the rate of growth of each cell line by counting the total number 
of cells in duplicate every day for 7 days, using following Neubauer chamber 
formula: [(n° of cells ∙ 104) / n° of squares] ∙ dilution factor. 
Somatic cell hybrids derived from fusion between human cells and Chinese 
hamster ovary (CHO) were obtained from Prof. Mariano Rocchi’s group at 
 
Cohort Type Age Gender D4Z4 length Strain Muscle MRC 
01 CTRL 46 Male >48 kb 160 Biceps Full 175 Deltoid Full 
01 FSHD 42 Male 18 kb 157 Biceps 4+/5 172 Deltoid 4+/5 
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Department of Anatomical Pathology and Genetics (DAPeG, University of 
Bari, Italy). Hybrids were cultured in RPMI 1640 supplemented with 10% 
FBS, 2 mM L-glutamin and 1% Pen/Strep. 
Reached 70-80% of confluence, cells were re-plated at lower cell density to 
prevent cell death. PCP (Partial Chromosome Painting) libraries are free to 
access at http://biologia.uniba.it/rmc/. Details about human/CHO hybrids used 
in this study are reported below. 
 
 
 
 
2.2 AZA-TSA treatment 
 
Human/CHO hybrids were seeded at low confluence in growth medium, in 
order to perform a 72h 5-Aza-2’-deoxycytidine (AZA) and 12h Trichostatin A 
(TSA) treatment. The day after plating, AZA (Sigma) was added to the 
medium at final concentration of 1 μM. Every 24h and for other 2 days, the 
medium was replaced with fresh medium containing 1 μM AZA. For the last 
12h of treatment, TSA (Sigma) was added to the medium at final concentration 
of 1 μM. Cells were collected after 72h AZA and 12h TSA treatment for RNA 
extraction. 
 
RH4L319 (chr. 4) 
HYE7 (chr. 3) 
HY94BT1 (chr. Y) 
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2.3 RNA fractionation 
 
Cells were detached by treating with 1X Tripsin-EDTA (Euroclone), counted 
and centrifuged at 1000 rpm for 5’. The pellet was lysed with 175 μl/106 cells 
of cold RLN1 solution (50 mM Tris HCl pH 8.0; 140 mM NaCl; 1.5 mM 
MgCl2; 0.5% NP-40; 2 mM Vanadyl Ribonucleoside Complex) and incubated 
5’ in ice. Suspension was centrifuged at 4°C and 2000 rpm for 2’, and the 
supernatant, corresponding to cytoplasmic fraction, was transferred into 1.5 ml 
fresh tube. 
The pellet containing nuclei was treated with 175 μl/106 cells of cold RLN2 
solution (50 mM Tris HCl pH 8.0; 500 mM NaCl; 1.5 mM MgCl2; 0.5% NP-
40; 2 mM Vanadyl Ribonucleoside Complex) and incubated 5’ in ice. 
Suspension was centrifuged at 4°C and 13000 rpm for 2’, and the supernatant, 
corresponding to nuclear-soluble fraction, was transferred into 1.5 ml fresh 
tube. Pellet corresponding to chromatin-associated fraction was resuspended in 
RNase-free water. 
 
 
2.4 RNA extraction  
 
Total RNA extraction was performed by miRVana miRNA Isolation Kit 
(Ambion) or by ReliaPrep RNA Miniprep System (Promega). If miRVana Kit 
was used, DNase I (Thermo Fisher Scientific) treatment was performed 
separately after purification according .to the instruction of the manufacturer.  
All total RNA samples were quantified by using NanoDrop 2000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific) and the integrity was evaluated 
on 2100 Bioanalyzer System (Agilent Technologies) by using RNA 6000 Nano 
Kit (Agilent Technologies). In this study only RNA samples with an RNA 
Integrity Number (RIN) ≥8 were used. 
MicroRNA isolation was achieved by miRVana miRNA Isolation Kit 
(Ambion) following manufacturer’s small RNA species enrichment protocol. 
The NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific) 
was used for their quantification. 
 
39 
 
2.5 3’ Rapid Amplification of cDNA Ends (3’RACE) 
 
3’RACE of polyA+ transcripts was carried out following manufacturer’s 
instructions (Thermo Fisher Scientific). Retrotranscription was performed on 
500 ng of total RNA with SuperScript III First Strand Synthesis System 
(Thermo Fisher Scientific), using adapter-tailed oligo(dT). First amplification 
and nested PCR were performed by using Platinum Taq High Fidelity (Thermo 
Fisher Scientific). 
3’ RACE of polyA- was performed by SMART (Switching Mechanism at the 
5’ end of RNA Template) protocol, based on using of anchor-tailed random 
hexamers and riboguanosine oligonucleotides in order to exploit template-
switching reverse transcriptase activity. Indeed, this method takes advantage of 
hybridization between adapter-tailed riboguanosine oligonucleotides and 5’ 
cytosine tail added during reverse transcription. 
In detail, 100 ng of total RNA was added to 1 μl of dNTPs (10 mM each; 
Thermo Scientific) and 2 μl of pre-mixed anchor-tailed random hexamers (100 
μM), adapter-tailed riboguanosine template-switching oligos (100 μM), and 
trehalose (0.66 M; Sigma-Aldrich) and sorbitol (3.3 M; Sigma-Aldrich), two 
potent enhancers of cDNA synthesis and priming specificity. 
After heating at 65°C for 5’ to melt secondary structures of RNAs and 
replacing in ice for 1’, we collected the mixture by centrifugation and added 
the following reagents: 4 μl 5X First Strand Buffer (250 mM Tris-HCl (pH 
8.3), 375 mM KCl, 15 mM MgCl2), 1 μl DTT (0.1 M), 1 μl RNaseOut (40 
U/μl) and 1 μl SuperScript III RT (200 U/μl) in a final volume of 20 μl. The 
reaction mix was pre-incubated at 25°C for 5’ to facilitate random hexamers-
template priming, then we proceeded with heating at 50°C for 50’, followed by 
15’ at 70°C for RT inactivation. cDNA was finally incubate at 37°C for 20’ 
with RNase H. 
Pre-amplification step was performed in ice, adding 1 μl of cDNA (5 ng) to 3-5 
μl 3’-adapter primer (10 μM), 1 μl 5’-adapter primer (10 μM), 2 μl MgSO4 (50 
mM), 1 μl dNTPs (10 mM each), 5 μl 10X High Fidelity PCR Buffer (600 mM 
Tris-SO4 (pH 8.9), 180 mM (NH4)2SO4), 0.5 μl Platinum Taq High Fidelity 
(5U/μl) and DNase-free distilled water to final volume of 50 μl. 
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After pre-incubation at 45°C for 1’ and at 94°C for 2’, we set up the following 
program: 5 x (30’’ 94°C, 30’’ 72°C), 5 x (30’’ 94°C, 30’’ 70°C), 25 x (30’’ 
94°C, 1.5’ 68°C), 10’ 68°C. The optimal ratio between 5’- and 3’-adpeter 
primers was found between 1:3 and 1:5. Respectively, these 5’- and 3’-adapter 
sequences were used: 5’-GTATCAACGCAGAGTACGATTGATG-3’ and 5’-
GACCACGCGTATCGATGTCGAC-3’. 
Pre-amplification reaction was useful to enrich low abundant transcripts and  
reduce background in following nested sequence-specific PCR step. Ever in 
ice, 1 μl of pre-amplification product was added to 1 μl nested 3’-adapter 
primer (10 μM), 1 μl tag-specific primer (10 μM), 2 μl MgSO4 (50 mM), 1 μl 
dNTPs (10 mM each), 5 μl 10X High Fidelity PCR Buffer (600 mM Tris-SO4 
(pH 8.9), 180 mM (NH4)2SO4), 3 μl of pre-mixed 1,2-propanediol (0.81 M; 
Sigma-Aldrich), trehalose (0.66 M; Sigma-Aldrich) and betaine (2.2 M; Sigma-
Aldrich), 0.5 μl Platinum Taq High Fidelity (5U/μl) and DNase-free distilled 
water to final volume of 50 μl. On thermal cycler we set up the following 
program: 2 min 94°C, 25 x (30’’ 94°C, 30’’ 65°C, 1’ 68°C), 10 min 68°C. 
For both 3’RACE standard protocol and alternative method, after every PCR 
step an aliquot of reaction mix was loaded on 1% TAE (40 mM Tris acetate pH 
8.2; 1 mM EDTA) agarose gel, for careful evaluation of amplification patterns. 
 
 
2.6 Deep sequencing 
 
Sequencing of 3’RACE products (derived from both experimental procedures) 
was performed on MiSeq sequencing platform (Illumina), in cooperation with 
ITB-CNR (Segrate, Milan, Italy). Library preparation was carried out by PCR, 
using barcoded anchor-tailed primers and Platinum Taq High Fidelity protocol 
(Thermo Fisher Scientific). Libraries was purified by Agencourt AMPure XP 
(Beckman-Coulter) and evaluated on 2200 TapeStation (Agilent Technologies) 
by D1000 ScreenTape assay (Agilent Technologies). Library was sequenced 
using paired-end strategy. 
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2.7 One-step strand-specific RT-PCR and nested PCR 
 
Strand-specific RT-PCR (ssRT-PCR) was performed combining the cDNA 
synthesis and amplification reactions in the same tube (one-step). We added 10 
μl of total RNA (500 ng) to 2 μl primers mix (anchored strand-specific RT 
primer (100 μM) and PCR forward and reverse (8 μM each) oligonucleotides), 
1 μl dNTPs (10 mM each), 1 μl DTT (0,1 M), 1 μl RNase Out (40U/μl), 5 μl 
10X one-step RT-PCR buffer (200 mM Tris HCl, 500 mM KCl, 15 mM 
MgSO4),  0,5 μl SuperScript III RT (200U/μl), 0,2 μl Platinum Taq High 
Fidelity (5U/μl) and DNase-free distilled water to final volume of 50 μl. 
Reaction mixture was heated at 65°C and temperature was gradually decreased 
by 1°C every minute. Reached 55°C, temperature was maintained for 45’ to 
synthesize cDNA, then increased to 94°C for 5’ to restore polymerase activity, 
followed by 15 cycles of amplification (30’’ 94°C, 30’’ 65°C, 1’ 68°C) and 5’ 
at 68°C of final elongation step. Terminate the reaction, first amplification 
product was stored to -20°C or used for nested PCR or qRT-PCR immediately. 
Nested PCR was performed added 1 μl of ssRT-PCR product to 1 μl nested 
forward primer (10 μM), 1 μl nested reverse primer (10 μM), 2 μl MgSO4 (50 
mM), 1 μl dNTPs (10 mM each), 5 μl 10X High Fidelity PCR Buffer (600 mM 
Tris-SO4 (pH 8.9), 180 mM (NH4)2SO4), 0.5 μl Platinum Taq High Fidelity 
(5U/μl) and DNase-free distilled water to final volume of 50 μl. On thermal 
cycler we set up the following program: 2 min 94°C, 30 x (30’’ 94°C, 30’’ 
65°C, 1’ 68°C), 10 min 68°C. Terminate the reaction, PCR product was then 
loaded on agarose gel for further evaluations. 
The anchored ssRT primers were: 
L4 (chr4): 5’-cgactggagcacgaggacactgaGCCTTTACAAGGGCGGCTGG-3’ 
L17 (chrY): 5’-cgactggagcacgaggacactgaTGCAGCCTGCCTGTCTGCGT-3’ 
L26 (chr3): 5’-cgactggagcacgaggacactgaGTAGGTCTTACTAAGGGCCT-3’ 
First amplification primers for all chromosome-specific sequences were: 
5’-CGACTGGAGCACGAGGACACTGA-3’ 
5’-AATCTGGACCCTGGGCTCCGGAATGC-3’ 
as forward and reverse primers. Nested forward primers for chr4/Y and chr 3 
were: 5’-TGGCTGGACCTGCCTGCAGC-3’ and 5’-GCTGGCTGGCTGTCCG-3’. 
Common nested reverse primer was: 5’-CGTTCTCTGGTGGCGATG-3’. 
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2.8 Cloning and Sanger sequencing 
 
Amplicons of antisense transcripts obtained by nested PCR and loaded on 1.5% 
TAE (40 mM Tris acetate pH 8.2; 1 mM EDTA) agarose gel was extracted by 
using Wizard SV Gel and PCR Clean-Up System (Promega). Cloning was 
performed in DH5α competent cells by TOPO TA Cloning Kit for Sequencing 
(Thermo Fisher Scientific), following manufacturer’s instructions. Positive 
clones were screened by colony PCR, using T3 and T7 primers, then sequenced 
at Human Molecular Genetics Consortium (Monza, Italy). 
 
 
2.9 Quantitative Real-Time PCR 
 
qRT-PCR analysis was performed on 7900 HT Fast Real-Time PCR System 
(Applied Biosystem) by GoTaq qPCR Master Mix (Promega) to quantify 
antisense transcripts and the other genes of interest. 
In absence of endogenous normalizers for ssRT-PCR, the quantification was 
achieved by standard curve method. We used serial dilutions of known amount 
of antisense DNA amplicon (starting from in vitro transcribed RNA) in order to 
create standard curve and verify efficiency and linearity of reaction. Unknown 
sample quantity was determined by linear interpolation of Ct on standard curve 
graph and then represented as fold change over control myoblasts (T0). For 
gene expression analysis, we used instead comparative 2−ΔΔCt method, with 
GAPDH as endogenous normalizer. 
Thermal cycling conditions were 2’ at 94°C, followed by 40 cycles at 94°C for 
10’’ and 60°C for 30’’, for gene amplification, or by 40 cycles at at 94°C for 
10’ and 65°C for 1’, for antisense transcripts amplification. All qRT-PCR 
primers are listed in following page. 
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qRT-PCR primers 
Target Sequence (5’-3’) 
MYOD-F CCGCCTGAGCAAAGTAAATGA 
MYOD-R GCAACCGCTGGTTTGGATT 
MYF5-F CGAATGTAACAGTCCTGTCTGG 
MYF5-R AGGTTGCTCTGAGGAGGTGA 
MYOG-F TGCTCAACCCCAACCAGCGG 
MYOG-R TTCACTGGGCACCATGGGCTG 
MEF2A-F GTGTACTCAGCAATGCCGAC 
MEF2A-R AACCCTGAGATAACTGCCCTC 
MEF2C-F TTCCAGTATGCCAGCACCG 
MEF2C-R GGCCCTTCTTTCTCAACGTCTC 
DUX4-FL-F GAGCTCCTGGCGAGCCCGGAGTTTCTG 
DUX4-FL-R CTAAAGCTCCTCCAGCAGAGCCCGGTATTCTTCCTC 
TSC1-F TAGGGCACAATGAAGAGGCA 
TSC1-R CGCTTCTCCCATAGTCGTCT 
TSC2-F GACGCCTTAAAGAGCAGAGC 
TSC2-R GATGGATCTGGTCGAGGAG 
GβL-F ACGGCGTCAACAAGAACATC 
GβL-R GCAGTTAATGGGTGCGTTCA 
RAPTOR-F ACTGATGGAGTCCGAAATGC 
RAPTOR-R TCATCCGATCCTTCATCCTC 
RICTOR-F GGAAGCCTGTTGATGGTGAT 
RICTOR-R GGCAGCCTGTTTTATGGTGT 
AKT2-F CCCTTCTACAACCAGGACCA 
AKT2-R AACCTGTGCTCCATGACCTC 
PLD1-F AATCGTTGGAGGTTGGACTG 
PLD1-R AGACGGTGGATGACACATGA 
S6K1-F GCATGCTCCTACGCTGAACT 
S6K1-R TGTCCTCAGCTTCCCTGTCT 
MSTN-F CGCTACAACGGAAACAATCA 
MSTN-R GAGTCTCGACGGGTCTCAAA 
SMAD3-F GCCTGTGCTGGAACATCATC 
SMAD3-R TTGCCCTCATGTGTGCTCTT 
FOXO3-F AGTGGATGGTGCGCTGTGT 
FOXO3-R CTGTGCAGGGACAGGTTGT 
FOLL-F TGCACTCCTAAAGGCAAGATG 
FOLL-R CTGGGCAATCCGATTACAG 
GAPDH-F TTCACCACCATGGAGAAGGC 
GAPDH-R GGCATGGACTGTGGTCATGA 
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2.10 MiRNA retrotranscription and quantification 
 
Small RNA fraction isolated from control and FSHD myoblasts and myotubes 
was used for microRNA retrotranscription and amplification by miRCURY 
LNA Universal RT microRNA PCR (Exiqon), following manufacturer’s 
instructions. CTX (500 nM) was used as passive reference and qRT-PCR was 
performed on 7900 HT Fast Real-Time PCR System (Applied Biosystem). 
Custom primer sets for novel miRNAs was designed by Exiqon with its 
proprietary tool (https://www.exiqon.com/mirna-qpcr-designer). 
Data was analyzed with comparative 2−ΔΔCt method. We used has-miR-103a 
as endogenous control and nomalizer, and UniSp6 as RNA spike-in for 
transcription efficiency evaluation. Thermal cycling conditions were 10’ at 
94°C, followed by 45 cycles at 94°C for 10’’ and 60°C for 1’. Melting curve 
analysis was performed with SDS software v1.4 (Applied Biosystem).  
 
 
2.11 In vitro transcription 
 
Vector pMK-RQ (GeneArt) containing DUX4-AS2 consensus sequence 
flanked by T7 and SP6 promoters was treated with restriction enzyme in order 
to cutting out and use insert (541 bp) as template for in vitro transcription. 
Purified construct (10 μg) was incubated with 20 U of SfiI enzyme and 1X 
CutSmart Buffer (NEB) at 50°C for 1h. 
Reaction mix was loaded on 1.5% TAE (40 mM Tris acetate pH 8.2; 1 mM 
EDTA) agarose gel to evaluate cutting efficiency and isolate insert by gel 
extraction. Insert was purified from agarose slice by using Wizard SV Gel and 
PCR Clean-Up System (Promega) and assayed by Nanodrop 2000 UV-Vis 
Spectrophotometer (Thermo Scientific). 
About 1.85x1011 copies of insert (0.1 μg) was used to assemble reaction at 
room temperature with MEGAscript T7 Transcription Kit (Ambion) and 
MEGAscript SP6 Transcription Kit (Ambion) reagents, respectively for sense 
and antisense transcript synthesis and following manufacturer’s instructions. 
Transcription reaction mixture was incubated at 37°C for 4h and finally treated 
with 2 U of TURBO DNase at 37°C for 15’ to totally remove template DNA. 
45 
 
In vitro transcribed RNA was purified by using RNA Clean & Concentrator 
100 (Zymo Research), evaluated by run on 1.5% MOPS (20 mM MOPS pH 
7.0; 1 mM EDTA; 5 mM NaOAc) agarose-formaldehyde (37% formaldehyde 
to final concentration of 0.7 M; Sigma) gel and quantified by NanoDrop 2000 
UV-Vis Spectrophotometer (Thermo Fisher Scientific). 
 
 
2.12 5’end capping and 3’end biotinylation 
 
After in vitro transcription, 10 μg of purified DUX4-AS2 RNA was heated at 
65°C for 5’ to remove secondary structure and placed in ice for other 5’. 
Capping reaction was performed by using  Vaccinia Capping System (NEB), 
following manufacturer’s instructions. The reaction time was extended to 1h to 
improve capping efficiency. 
Capped RNA was purified by using RNA Clean & Concentrator 100 (Zymo 
Research) and resuspended in 6 μl of RNase-free water. 
Biotin labeling of DUX4-AS2 RNA was performed by using Pierce RNA 3’ 
End Biotinylation Kit (Thermo Fisher Scientific), following manufacturer’s 
instructions. Reaction was set up with 50 pmol of RNA and incubated 
overnight at 16°C. Before ligation, RNA was pre-heated at 85°C for 4’ in 
presence of 25% of DMSO to increase efficiency. 
Reaction byproducts was removed with Chlorophorm:isoamyl alcohol 24:1 
(Sigma), and labeled RNA was precipitated (1h at 20°C) with ice-cold 100% 
ethanol in presence of 20 μg/μl glycogen and 5M NaCl. Precipitate was 
centrifuged at 13000 g for 15’ at 4°C, supernatant removed and pellet washed 
with ice-cold 70% ethanol. Finally ethanol was removed and air-dried pellet 
resuspended in 20 μl RNase-free water. 
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2.13 RNA-protein pull down assay 
 
Interaction between DUX4-AS2 and DGCR8 complex was validated by RNA-
protein interaction assay using Pierce Magnetic RNA-Protein Pull-Down Kit 
(Thermo Fisher Scientific). 
Cell lysate of healthy myoblasts at 90% of confluence in 100 mm treated tissue 
culture dishes (Corning) was prepared using RIPA buffer [50 mM Tris HCl pH 
7.4; 150 mM NaCl, 0.1% SDS, 0.5% Deoxycholate Sodium, 1% NP-40 and 
protease inhibitor cocktail 1X (Prod. N. P2714-1BTL; Sigma)], extracting both 
cytoplasmic and nuclear protein by sonication in Branson Ultrasonic Bath 
(Hach), followed by 15 min of centrifugation  a 13000 rpm at 4°C to discard 
cell debris. 
Binding of labeled RNA (100 pmol) to pre-washed Streptavidin Magnetic 
Beads (15 μl) and loading of protein lysate (2 mg/ml) was performed following 
manufacturer’s instructions. RNA-binding proteins complex was eluted in 50 
μl of Elution Buffer provided by Pull-Down Kit for downstream application. 
Complementary sense RNA of DUX-AS2 was used as negative control. 
 
 
2.14 Long non-coding RNA, siRNA and miRNA transfection 
 
Myoblasts were plated in 60 mm (surface area 20 cm2) treated tissue culture 
dishes (Corning) to be 70-80% confluent at transfection. Capped DUX4-AS2 
RNA (5 μg) was transfected by using Lipofectamine MessengerMAX Reagent 
(Invitrogen) in Opti-MEM medium (Euroclone). Complementary sense RNA, 
in vitro transcribed from vector pMK-RQ-AST2, was used as negative control. 
Single strand miRNA as-miR-276-5p and as-miR-320-3p (60 pmol each), as 
well as siRNA against DUX4 (s196453, Thermo Scientific) were individually 
transfected by using Lipofectamine RNAiMAX Reagent (Invitrogen) in Opti-
MEM medium (Euroclone). The mirVana miRNA Mimic Negative Control #1 
(Ambion) was used as scrambled sequence. Cells were incubated at 37°C and 
monitored for 2 days, then we proceeded with RNA or protein extraction. 
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2.15 SDS-PAGE and immunoblotting 
 
Cell lysate was prepared using RIPA buffer [50 mM Tris HCl pH 7.4; 150 mM 
NaCl, 0.1% SDS, 0.5% Deoxycholate Sodium, 1% NP-40 and protease 
inhibitor cocktail 1X (Prod. N. P2714-1BTL; Sigma)], extracting cytoplasmic 
and nuclear protein by sonication in Branson Ultrasonic Bath (Hach), followed 
by 15 min of centrifugation  a 13000 rpm at 4°C to discard cell debris. Sample 
preparation and quantification, and western blot analyses were performed as 
previously described (Pisconti et al, 2006). After electrophoresis, polypeptides 
were electrophoretically transferred to nitrocellulose filters (Thermo Scientific) 
and antigens revealed by respective primary antibody and the appropriate 
secondary HRP-linked antibody, through enhanced chemiluminescence 
(LiteAblot Plus, Euroclone). In immunoblotting analysis, antibodies specific 
for MyoD (1:1000) (5.8A, monoclonal mouse, Thermo Scientific), MyoG, 
CAV3, DUX4 (1:1000) (P4H2, monoclonal mouse, Thermo Scientific), MSTN 
(1:1000) (6H12, monoclonal mouse, Thermo Scientific), TSC1 (1:1000) (PA5-
19502, polyclonal rabbit, Thermo Scientific), RAPTOR (1:1000) (24C12, 
monoclonal rabbit, Cell Signaling), RICTOR (1:1000) (53A2, monoclonal 
rabbit, Cell Signaling), GβL (1:1000) (86B8, monoclonal rabbit, Cell 
Signaling) and sarcomeric myosin MHC (1:10) (MF20, from Developmental 
Studies Hybridoma Bank) were used. 
 
 
2.16 Immunofluorescence 
 
Cell immunofluorescence was performed as previously described (Brunelli et 
al, 2004), using antibodies specific for Desmin (1:20) (D8281, polyclonal 
rabbit, Sigma Aldrich), Ki67 (1:250) (SP6, monoclonal mouse, Abcam), MyoD 
(1:500) (5.8A, monoclonal mouse, Thermo Scientific) DUX4 (1:100) (P4H2, 
monoclonal mouse, Thermo Scientific), M-chaderin (1:200) (PA5-47578, 
polyclonal sheep, Thermo Scientific) and sarcomeric myosin MHC (1:4) 
(MF20, from Developmental Studies Hybridoma Bank). Appropriate 
secondary antibodies conjugated with Alexa 488 (green, Cell Signalling) or 
48 
 
Alexa 568 (red; Cell Signalling) were used for fluorescence detection. Nuclei 
were stained with Hoechst Stain Solution (H6024, SIGMA). 
Fluorescent images were taken on confocal laser scanning microscope (Zeiss 
Lsm 01, Biorad mrc 600, Biorad 1024) by using 12× magnification. Images 
showing double or triple fluorescence were separately acquired by using 
appropriate filters, and the different layers were merged and analyzed with 
ImageJ software. 
 
 
2.17 Flow cytometry 
 
Cell were detached by treating with 1X Tripsin-EDTA (Euroclone), counted 
and centrifuged at 1000 rpm for 5 min, then washed with PBS and incubated 
15 min in PBS supplemented with 5% of heat-inactivated calf serum to block 
non-specific sites. Incubation with primary antibody was performed for 15 min 
at room temperature. When secondary antibody was needed, cells were stained 
with AlexaFour 488-conjubated goat anti-mouse IgG (1:100) for 30 min at 
4°C. Cells were assayed by using  PE-conjugated CD56 (HCD56, monoclonal 
mouse, BioLegend) and anti-fibroblasts antibodies (TE7, monoclonal mouse, 
Sigma-Aldrich). The acquisition process was stopped when 15,000 events were 
collected in the population gate. 
 
 
2.18 Target prediction, gene ontology and pathway analysis 
 
For novel miRNA target prediction we mainly used miRTar tool (Hsu et al, 
2011), an integrated system, based on miRanda, PITA and TargetScan 
algorithms, setting cutoff of minimum free energy (MFE) of the miRNA-target 
duplex to -14 kcal/mol and threshold of total score to 140. We also used 
RNAhybrid (Rehmsmeier et al, 2004) for miRNA-3’UTR negative normalized 
MFE calculation (cutoff of -12 kcal/mol and seed 2–8 allowing G:U wobble 
pairs) and RNA22 (Miranda et al, 2006) for evaluation of miRNA-5’UTR/CDS 
interaction, using following parameters: sensitivity of 63%, specificity of 61%, 
seed size of 7 allowing 1 un-paired bases and no limit of G:U wobble pairs, and 
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maximum folding energy of -12 kcal/mol. Putative targets were finally tested 
for miRNA repression strength by using miRmap (Vejnar et al, 2013), then 
subjected to analysis of Gene Ontology terms and KEGG pathway enrichment 
by DAVID (Database for Annotation, Visualization and Integrated Discovery) 
(da Huang et al, 2009). 
 
 
2.19 Sequence homology-based conserved domain analysis 
 
Search of DUX4-fl conserved domains was performed by using PSI-BLAST 
tools, to align amino acid sequence of DUX4-fl with non-redundant sequences 
collected in several datasets: GenBank, RefSeq, PDB, SwissProt, PIR and PRF. 
Alignment score was determined by BLOSUM62 matrix and setting following 
gap coasts: 11 for existence and 1 for extension. Statistical significance 
threshold to include a sequence in PSSM (Position Specific Score Matrix) on 
next alignment iteration was 0.005. Analysis was aborted after three iteration 
cycles. Obtained sequences were clustered by using CLANS software, basing 
on homology level, query covering and phylogenetic distance. 
 
 
2.20 Secondary structure analysis  
 
Prediction of α-helix and β-sheet motifs was obtained from PSIPRED (Buchan 
et al, 2013) and Jpred4 (Drozdetskiy et al, 2015) servers. Trans-membrane and 
coiled-coils topology were sought by TMHMM (Krogh et al, 2001) and COILS 
(Lupas et al, 1991) algorithms. Low complexity regions were predicted by 
CAST and intrinsic protein disorder was evaluated by DisEMBL tools, using 
following algorithm parameters: 8 of Savitzky-Golay smoothing frame, 8 of 
minimum peak width, 4 of maximum join distance; and predictors stringency 
values: 1.20 (Coils and Remark465 threshold) and 1.40 (hot loops threshold). 
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2.21 De novo modeling and structure validation 
 
DUX4-fl was submitted to Rosetta software  for full-chain structure prediction. 
Models and conformational domains were further evaluated by using ProSA 
(Wiederstein et al, 2007) and QMEAN (Benkert et al, 2009), for z-score 
calculation, and MolProbity (Chen et al, 2010), for Ramachandran plot and 
other geometric properties evaluation, structure-validation web services, then 
visualized by PyMOL Molecular Graphics System, v.1.8. 
 
 
2.22 Molecular dynamics simulation 
 
We carried out simulations using GROMACS 4.5 (Hess et al, 2008) and we 
used the trjconv, rms and gyrate tools in the GROMACS package to analyze 
the simulation data. We performed energy minimization in all-atom OPLS or 
GROMOS96 43a1force fields, heating from 0 K to 300 K, then running the 
NPT simulation for 2 ns at 300 K at 1 bar pressure. 
 
 
2.23 Statistical analysis 
 
For qPCR data of antisense transcript expression a one-tail, unpaired t-test was 
used. For all other immunofluorescence, qPCR and western blot experiments, 
p-value was evaluated by two-tail, paired t-test. All error bars on the graphs are 
referred to standard deviation.  
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Chapter III - Results 
 
 
 
3.1 Characterization of FSHD myogenesis 
 
 
3.1.1 FSHD myoblasts exhibit early commitment to myogenesis, 
fusing into disorganized myotubes, when compared to control 
muscle cells 
 
Previous works reported that affected myoblasts fuse to give rise either thin 
and branched myotubes or abnormally swelled myotubes with disorganized 
nuclei distribution, compared to large branched myofibers with well-aligned 
nuclei deriving from healthy skeletal muscle cells (Barro et al, 2010; 
Vanderplanck et al, 2011). 
Despite of these morphological alterations, the molecular mechanisms driving 
pathologic differentiation are still poorly understood. Indeed, several studies of 
gene expression analysis have been focused on identification of dysregulated 
pathways and toxic effects of 4q35.2 genes, explaining the altered outcome of 
FSHD myogenesis, but omitting dynamics underlying myoblast commitment, 
migration and fusion into myotubes. 
In this study, we took advantage of immortalized myoblasts derived by biceps 
and deltoid muscle biopsies recovered from multiple cohorts of FSHD donors 
and their healthy first-degree relatives (Homma et al, 2012). In particular, we 
mainly used 157A (affected biceps) and 160U (unaffected biceps) from cohort 
01. In necessary, both 172A (affected deltoid) and 175U (unaffected deltoid) 
cell strains was used as well (see Material and Methods for details). 
At the outset, we evaluated cell identity and purity by flow cytometry, in order 
to exclude the presence of non-muscular contaminants (CD56 negative cells) 
retained during clonal selection of immortalized strains. As expected, in each 
sample analyzed, CD56+ cells were more than 99%. (Fig. 1A). Secondly, we 
analyzed the growth curves to estimate propagation efficiency and velocity of 
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each cell line in proliferation medium (LHCN), finding that both biceps- and 
deltoid-derived affected myoblasts are characterized by a slower growth rate 
than controls (Fig. 1B). 
 
 
 
Fig. 1 - A) Analysis by flow cytometry of expression of CD56 (muscle-specific maker) and 
TE7 (fibroblast-specific marker) in biceps control and FSHD myoblasts. B) Seven days growth 
curves of biceps control and FSHD myoblasts. 
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We choose to inspect the entire differentiation process, through setting up of 
time course experiments. Both FSHD and healthy myoblasts were then 
switched to differentiation medium containing 2% of horse serum (HS) and 
analyzed every 2 days until the complete maturation of myotubes (6-8 days).  
 
 
 
Fig. 2 - A) Phase contrast microscope images of control and FSHD muscle cells during 
different stages of differentiation. B) Analysis by immunofluorescence of healthy and FSHD 
cells after 2-4 days of differentiation for marker expression of cell proliferation (Ki67, in red) 
and differentiation (MF20, in green). Nuclei were stained with DAPI (blue). Fusion index was 
compared between control and FSHD. Error bars indicate standard deviation. N = 6; * p-value 
< 0.05. 
 
Morphological evaluation and fusion rate calculation were performed by 
microscopy techniques, whereas expression level of different muscle-specific 
markers was assayed by qRT-PCR, western blot and immunofluorescence too. 
Results supported hypothesis of early differentiation in FSHD myoblasts, when 
compared to healthy controls. Moreover, we observed disorganized migration 
and uncontrolled fusion in affected cells, which starts after two days in 
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differentiation medium and proceeds without a correct alignment along the 
primary myotubes (Fig. 2A). 
 
 
 
Fig. 3 - Phase contrast microscope images of control and FSHD proliferating myoblasts. Dark 
flanges are appreciable on plasma membrane of affected cells. 
 
As revealed by immunofluorescence, the fusion index (which is referred to as 
number of nuclei into myotubes over the total number of nuclei) of FSHD 
myoblasts is significantly higher than controls (Fig. 2B). 
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Fig. 4 - A) MyoD protein and Myf5 mRNA levels were evaluated by western blot and qRT-
PCR respectively, in control and FSHD muscle cells during different stages of differentiation. 
GAPDH was used as normalizer. B) Quantification by immunofluorescence of Ki67+ and 
MyoD+ control and FSHD proliferating myoblasts. Nuclei were stained with DAPI (blue). 
Error bars indicate standard deviation. N = 5; * p-value < 0.05. 
Overall, some morphological differences have been also recognized during the 
first stages of differentiation: FSHD myoblasts do not stretch and polarize 
themselves, showing a disordered topographic patterning of cell-surface fusion 
interfaces (Fig. 3). 
Myogenic determination factors Myf5 is significantly down-regulated in FSHD 
myoblasts versus controls, suggesting that affected cells are prone to escape 
cell cycle and start differentiation (Fig. 4A). Particularly, to exclude that 
affected proliferating cells had already started the differentiation program, we 
evaluated the ratio of Ki67+ nuclei over total of nuclei, without finding 
variations (Fig. 4B).  
 
 
 
Fig. 5 - MF20 protein and MEF2a/MEF2c mRNA levels were assayed by western blot and 
qRT-PCR respectively, in biceps control and FSHD muscle cells, during different stages of 
differentiation. GAPDH was used as endogenous normalizer. Error bars indicate standard 
deviation. The statistical significance was evaluated between control and FSHD, at same time 
point. N = 3; * p-value < 0.05. 
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No significant differences, instead, were observed by western blot in MyoD 
levels (Fig. 4A), despite of higher number of MyoD+ nuclei was detected in 
FSHD myoblasts (Fig. 4B). Conversely, other muscle-specific markers, such as 
Mef2a, Mef2c and MF20, confirmed early differentiation in affected cells. 
Interestingly, both Mef2a and Mef2c, following a significant increase of their 
expression levels in FSHD myoblasts at T2, appeared lower than controls at T4 
(Fig. 5). Similar results were obtained on deltoid-derived cell lines, although 
their differentiation rate, in FSHD, appeared slightly slower compared to 
biceps-derived myoblasts (data not shown). 
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3.1.2 DUX4 full-length isoforms are expressed in FSHD and 
control myoblasts and increase during myogenic differentiation 
 
We evaluated our cell model for DUX4 expression, particularly for its toxic 
full length isoforms. Protein quantification was performed by western blot, 
during all stages of differentiation. Interestingly, we found DUX4-fl expressed 
in both control and FSHD cell lines, observing an increase of its level during 
myoblast fusion and myotubes formation processes. 
Surprisingly, no quantitative difference was highlighted for DUX4-fl between 
control and FSHD, discrediting the exclusively pathological role attributed to 
this protein (Fig. 6). 
By using an antibody (P4H2) against C-terminus of DUX4, we also detected 
DUX4-fl2, occurring preferentially during late stages of muscle differentiation. 
 
 
 
Fig. 6 - Protein levels of DUX4 full length isoforms in control and FSHD muscle cells during 
differentiation. GAPDH was used as endogenous normalizer. Error bars indicate standard 
deviation. The statistical significance was evaluated between control and FSHD, at same time 
point. N = 3; * p-value < 0.05. 
 
Moreover, according to evidences of premature myogenesis in FSHD cell lines, 
DUX4-fl2 was found from the fourth day, in affected cells, whereas in healthy 
control appeared after 6 days only (Fig. 6). Results were comparable by using 
myoblasts deriving from both biceps and deltoid (not shown). 
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3.1.3 Use of knockout serum replacement (KOSR) as alternative 
to HS accelerates myogenic differentiation in FSHD and control 
myoblasts by enhancing DUX4 expression 
 
Previous studies demonstrated that DUX4 expression is negatively regulated 
by Wnt/β-catenin signaling (Block et al, 2013). The LHCN medium we used to 
grow myoblasts contains dexamethasone, which is reported to disrupt Wnt/β-
catenin signaling (Almeida et al, 2011). Therefore, we expected to find DUX4 
expression favored in proliferation medium. On the other hand, dexamethasone 
has been shown to increase apoptosis and ROS generation (Oshima). 
Analogously, Wnt/β-catenin signaling has been observed to be suppressed by 
serum deprivation in cancer cells (Khan et al, 2007). This finding could explain 
DUX4 increasing after switch to differentiation medium. However, latest work 
demonstrated that growing myoblasts without dexamethasone and replacing 
HS with the artificial serum KOSR (Life Technologies, Frederick, MD, USA) 
in differentiation medium, DUX4 significantly increased by Wnt suppression 
and consequently skeletal muscle cells appeared to be protected from oxidative 
stress (Pandey et al, 2015). 
For these reasons, we chose to modify the cell culture conditions according to 
Pandey’s protocol, removing dexamethasone in growth medium and replacing 
2% HS with 10% KOSR in differentiation medium. As previously observed 
(Pandey et al, 2015), the enhancement of DUX4 expression correlates with 
increased differentiation rate in both control and FSHD muscle cells (Fig. 7A): 
complete myotube maturation, in KOSR-added medium, occurs after 4-6 days 
only, instead of 6-8 days in traditional differentiation medium. 
However, affected myoblasts remained able to fuse into myotubes faster than 
healthy cells. Indeed, as confirmed by western blot analysis of several markers 
of differentiation, such as MyoD, MF20, MyoG and caveolin-3 (CAV3), new 
culture conditions enhanced FSHD characteristics of altered myoblast fusion 
and aberrant myotubes formation (Fig. 7B). 
The model made time course experiments more reproducible and manageable, 
compared to conventional culture conditions of both immortalized or primary 
muscle cells. Consequently, in order to overcome limits of previous culture 
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methods, mainly concerning negative effects on D4Z4 transcription efficiency, 
we decided to implement this protocol for most of the following experiments. 
 
 
 
Fig. 7 - A) Phase contrast microscope images of control and FSHD muscle cells during 
differentiation in KOSR-added medium. B) Western blot analysis of muscle-specific markers, 
during differentiation in KOSR-added medium. GAPDH was used as endogenous normalizer. 
Error bars indicate standard deviation. The statistical significance was evaluated between 
control and FSHD, at same time point. N = 3; * p-value < 0.05. C) Comparison of DUX4 
protein level in myoblasts induced to differentiate in HS- or KOSR-added medium. 
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3.2 Characterization of D4Z4-derived miRNAs 
 
 
3.2.1 Analysis of the transcription start site distribution within 
D4Z4 macrosatellite and DUX4-like genes 
 
Project started by querying FANTOM database (http://fantom.gsc.riken.jp/) for 
transcription start sites (TSSs), in order to evaluate their distribution patterns in 
D4Z4 repeat array and other DUX4-like loci in skeletal muscle samples. We 
used configuration for FANTOM5 human promoterome updated with phase 2 
data (Erik et al, 2015) and including tracks for Genecode v19 transcript 
expression, promoters filtered by Genecode v19 +/- 50bp 5’ end, and Entrez 
gene expression. Data integration, exploration and analysis were performed by 
using Zenbu, a visualization system improved for RNAseq, CAGE and other 
next-generation sequencing tag-based data. 
All DUX4-like genes annotated in human genome database (hg19, GRCh37) 
are listed in table 1. We took into account tags included in the intron-less open 
reading frame of each DUX4 locus plus ~500 bp 5’/3’ ends. 
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Datasets we used for TSS pattern analysis have been derived from tag-based 
sequencing results of CAGE libraries prepared from total RNA of human 
skeletal muscle samples at different developmental and differentiation stages 
(Table 2). Platform employed for strand-specific high-precision sequencing of 
CAGE-defined TSSs was the HeliScope Single Molecule Sequencer. 
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In Zenbu genome browser, we collected datasets in several tracks, according to 
cell type, development stage or experimental features. By signal histogram, 
each track show genomic position and orientation (green for sense and violet 
for antisense strand) of the TSSs, and their relative expression level measured 
as tags per million (tpm). 
Altogether, sense and antisense TSS distribution within DUX4 loci localized 
on different chromosomes appears to be significantly variable. Analogously, 
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changing of CAGE tag patterns in muscle cells can also occur when compared 
among different stages of development and differentiation. The TSSs within 
D4Z4 repeat array, as well as within homologous macrosatellite on 10q26, are 
equally distributed in sense and antisense orientation along DUX4 locus, 
without significant differences between adult and fetal muscle cells (Fig. 8A). 
Conversely, both DUX4L9 (alias DUX4c) and DUX4L26 (on chromosome 3) 
show a significant increase of density of the sense/antisense TSS signals at 5’ 
of DUX4 ORF during adult myogenic differentiation when compared to adult 
myoblasts and fetal muscle cells (Fig. 8B and 9B). 
TSSs within DUX4-like loci on chromosome Y (DUX4Y1-4) are particularly 
enriched during embryonic rather than adult myogenesis (Fig. 9A). Moreover, 
very few signals of transcriptional activity were found on 12p11.1 (DUX4L27), 
20q11.1 (DUX4L32-34) and acrocentrics (data not shown). 
Overall, no significant differences at quantitative level were found between 
sense and antisense tags; indeed, data suggests that transcriptional activity can 
involve both strands, in particular on chromosomes 3 and Y, potentially giving 
rise to several transcripts which may be homologous to D4Z4-derived DUX4 
mRNA and, analogously, to the three antisense lncRNAs found on 4q35.2. 
Of these antisense lncRNAs, in particular, we chose to focus our valuation on 
transcript overlapping the 5’ of DUX4 ORF, that, according to HUGO Gene 
Nomenclature Committee (HGNC) guidelines, we renamed DUX4-AS2, since 
it is the second antisense transcript reported along DUX4 gene. 
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Fig. 8 - A) Graphical view of DUX4L2/DUX4L15 (chromosome 4/10) gene. Tag expression 
(measured in tpm) is visualized as a signal-height graph along genomic coordinate space, in 
sense (green) and antisense (violet) orientation. First track reports DNAse I hypersensitive sites 
in control and FSHD skeletal muscle; second and third tracks show TSSs in adult myoblast and 
in fetal multinucleated muscle cells, respectively. Vertical orange line highlights the 5’ of 
DUX4-AS2. B) Graphical view of DUX4L26 (chromosome 3) gene. First track reports DNAse 
I hypersensitive sites in control and FSHD skeletal muscle cells; second and third tracks show 
TSSs in adult myotubes and myoblasts, respectively; fourth track reports those found in fetal 
multinucleated muscle cells. Vertical orange line highlights the 5’ of the putative antisense 
transcript, homologous to DUX4-AS2. 
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Fig. 9 - Graphical view of A) DUX4L9 (or DUX4c - chromosome 4) and B) DUX4L17 
(chromosome Y) gene. First track reports DNAse I hypersensitive sites in control and FSHD 
skeletal muscle; second and third tracks show TSSs in adult myotubes and myoblasts, 
respectively; fourth track reports those found in fetal multinucleated muscle cells. Vertical 
orange line highlights the 5’ of the putative antisense transcripts, homologous to DUX4-AS2. 
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3.2.2 Evidences of alternative TSSs for DUX4-AS2 (4q35.2) and 
its putative homologous 
 
Focusing our investigation on DUX4-AS2 transcript, as reported by Snider and 
colleagues, and analyzing CAGE data on chromosome 4/10 (DUX4L1-8/L10-
15), we found three TSSs very close to 5’ of DUX4-AS2: one (-3 bp) in fetal 
and two (-4 and +8) in adult myoblasts (~0.31 tpm), in association with a peak 
of DNAse I sensitivity reported in both healthy and FSHD samples (Fig 8A). 
Moreover, we also tried to map raw data deriving from both skeletal muscle 
PolyA+ (SRX082584) and PolyA- (SRC084669) RNAseq experiments. 
Intriguing, we found the sequence of an antisense transcript identical to DUX4-
AS2, but starting 68 bp upstream and perfectly coinciding with another TSS in 
adult myoblast. In the same datasets (SRX084669), we also come across a 
sequence of 78 bp in length overlapping one of the proximal miRNA-sized 
fragments discovered by Snider and colleagues (Fig. 10). 
 
 
 
Fig. 10 - Genomic sequence (strand plus) upstream 5’ of DUX4-AS2 (red arrow). Mapping of 
lncRNAs found in dataset SRX084669 are also reported (orange arrow and green line). Yellow 
lines represents miRNA-sized fragments discovered in this region (numbers refer to nt from 
MAL codon of DUX4 ORF). Violet vertical lines indicate TSSs observed in adult myoblasts. 
 
These evidences, in addition to the several TSSs located more upstream and 
downstream (as close as ~31 bp) of the 5’ of DUX4-AS2, support hypothesis 
that this antisense transcript could undergo alternative transcription initiation 
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and that, furthermore, could be non-polyadenylated, since we have not found 
matches within the dataset of PolyA+ RNAs. 
The putative 5’ of homologous transcripts, in antisense orientation to DUX4c 
and DUX4L26 genes, showed to be closed to several TSSs in adult skeletal 
muscle cells as well (Fig. 8B and 9B respectively). DNAse hypersensitivity 
sites corroborated hypothesis of transcriptional activity along region of origin 
of the putative DUX4-AS2 homologous on DUX4L26, but not on DUX4c 
locus, where we strangely observed a break in the signal pattern of chromatin 
accessibility. 
No match was found within DUXY repeats, pointing to genomic coordinates 
corresponding to hypothetical 5’ of DUX4-AS2 homologous transcripts. As 
shown in figure 9A for DUXY3 (DUX4L17), the closest TSS, in adult muscle 
cells, is over 50 bp downstream. Pattern of chromatin accessibility sites shows 
a significantly increase approaching 5’ of DUXY3 gene, suggestive of putative 
antisense transcription activity shifted downstream compared to that of other 
loci. Conversely, on DUX4L27 (chromosome 12), despite of general shortage 
of transcription signals, the few we found were concentrated around region of 
homology with the 5’ of DUX4-AS2 (data not shown).  
Overall, mapping of CAGE tags deriving from repetitive region is affected by 
low accuracy, hence these evidences remain mere conjectures. We then chose 
to set up 3’RACE experiments, in order to confirm, or exclude, the existence of 
this class of homologous antisense transcripts from DUX4-like gene family.  
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3.2.3 Experiments of 3’RACE reveal that DUX4-AS2, as well as 
its putative homologous, is non-polyadenylated 
 
The designing of 3’RACE primers was affected by both technical requirements 
(i.e. accomplishing high stringency conditions in order to reduce bias affecting 
technique itself) and the need to amplify in the same reaction all hypothetical 
DUX4-AS2 homologs deriving from different chromosomes. In order to avoid 
no amplification of some transcripts because of their possibly different 
transcription initiation sites, we choose to fix the sequence-specific primer 
annealing position 109 nt downstream the 5’ end of DUX4-AS2 characterized 
by Snider and colleagues, maintaining pair specificity of primer to each 
putative antisense homologous sequence, as shown in figure 11. 
 
 
 
Fig. 11 - 3’RACE forward primer position along DUX4-AS2. Sequence of primer (violet) is 
aligned to different DUX4-like genes. All mismatch between the sequences are highlighted. 
 
Experiments of 3’RACE was then performed on total RNA extracted from 
control and FSHD immortalized myoblasts and myotubes (7 days of 
differentiation). We used both the standard protocol, by using adapter-tailed 
oligo(dT), and a modified SMART (Switching Mechanism at the 5’ end of 
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RNA Template) approach, by using adapter-linked random hexamers, in order 
to extend PolyA+ and PolyA+/PolyA- transcripts respectively (see Materials 
and Methods for details). 
The 3’RACE products were evaluated by agarose gel electrophoresis (Fig. 12). 
For all RNA samples, when SMART approach was used, we observed a less 
intense smear and a single specific amplicon of about 400-450 bp, whereas the 
standard protocol led to a variable amplification pattern and most faint bands.  
 
 
 
Fig. 12 - Agarose gel electrophoresis of 3’RACE products, using oligo(dT) (left) or random 
hexamers (right) on total RNA extracted from cohort 01 control and FSHD myoblasts (prol) 
and myotubes after seven days of differentiation (7 dd). Black arrow indicates specific 
amplification obtained by polyA- 3’RACE protocol. 
 
By Illumina MiSeq platform, paired-end sequencing of amplification products 
deriving from both 3’ end extension approaches confirmed our hypothesis that 
DUX4-AS2 was non-polyadenylated. Indeed, preliminary alignment of total 
reads, performed by MiSeq Reporter analysis software to human genome 
database (h19) showed specific mapping to DUX4-like loci obtained after 
using of adapter-linked random hexamers only, as reported in table 3. 
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3.2.4 Analysis of sequencing suggests the presence of at least 
three different antisense transcripts from DUX4 gene family 
 
As previously explained, the goal of 3’RACE we set up was to amplify several 
transcripts in the same reaction. For this reason, 3’RACE experiments was 
designed as multi-template PCR, where a unique specific primer potentially led 
to enrichment of an heterogeneous class of sequences. Since DUX4-like loci 
have a high degree of homology, deep sequencing data analysis was performed 
to ensure assignment of correct chromosomal derivation of most of the 
sequences, minimizing effects of errors deriving from amplification and 
sequencing reactions on mapping accuracy. 
Initially, we needed to compute the Levenshtein distance between D4Z4 repeat 
and other DUX4-like loci (reverse strand) reported in human genome database 
(hg19, GRCh37), from 5’ (corresponding to 3’RACE primer position) to 3’ end 
of putative antisense transcripts we are looking for (~445 bp). 
Levenshtein distance between two string, also named edit distance, is closely 
related to pairwise string alignment and represent the minimum number of 
single-character edit (i.e. insertion, deletion or substitution) required to change 
one string into the other. Mathematically, Levenshtein distance between two 
sequence a and b (of length |a| and |b| respectively) is given by leva,b(|a|,|b|), 
defined as:  
 
  leva,b(i, j) =  
⎩
⎪
⎨
⎪
⎧max(i, j)min�leva,b(i − 1, j) + 1leva,b(i, j − 1) + 1leva,b(i − 1, j − 1) + 1(ai≠bj)    
 
where 1(ai≠bj) is the indicator function equal to 0 when ai = bj and 1 
otherwise.  
As shown in figure 13, antisense strand of D4Z4 repeats (4q35.2) gradually 
diverges from its homologous sequences on other DUX4-like loci as they 
approach to 3’ end and moving away from the open reading frame. DUX4-like 
loci mapping to 10q26 region, which share the same cluster organization with 
D4Z4 macrosatellite, represent the only exception to this trend. 
if max(i, j) = 0 
otherwise 
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Since sequences on 4q35.2 and 10q26 are very close (leva,b(i,j) = 2), we have 
not been able, during sequencing analysis, to discriminate multi-mapping reads 
deriving from these two regions, therefore we will refer to them as 4q/10q 
sequences, without further specification. 
Slightly divergent sequences are represented also by those of DUXY1-4 loci, 
with edit distance of 49, 57, 47 and 39 respectively, and that mapping on short 
harm of chromosomes 14 (leva,b(i,j) = 50). Unlike other DUX4-like sequences, 
their distribution of mismatches is particularly uniform and is characterized by 
several indel polymorphisms. Moreover, pairwise alignment of repeats on 
chromosome Y was further investigated. 
All four DUXY loci, rather than repeated units on 4q35.2 and 10q26, have 
suffered microduplications and/or microdeletions events which decreased their 
degree of identity (≤ 90%), as it has been previously reported (Schmidt et al, 
2009). 
On the other hand, DUX4L26 (chromosome 3), DUX4L27 (chromosome 20) 
and DUX4L9 (DUX4c), that heavily diverge from D4Z4 repeated sequences 
(leva,b(i,j) > 100), share a high level of homology (≥ 95%), necessitating a 
closer study of distribution of pairwise edit distances. 
The main problem of univocal alignment of multi-template PCR products 
derive from both DNA polymerase mutation rate and template-switching 
occurring during each replication cycle to the extent that they change the 
Levenshtein distance between two different starting sequences. 
Also PCR-based library preparation and sequencing itself introduce variations, 
therefore all reads take with a given number of artifactual mutations according 
to a specific probability distribution. A single mutational event affects 
Levenshtein distance, increasing or decreasing it. 
Assume we have two sequences N and M with n and m nucleotides, where n ≠ 
m; their distance is equal to d + ∑ gk, where d represent mismatches between 
sequences and ∑ gk the total number of gaps of length k. 
If a mutation happens (with mutation rate μ) in any of d nucleotides of 
sequence N, changing it to the nucleotide which is on the same position of the 
sequence M, or analogously, if a indel error (with frequency λ) reduces k length 
of gap between the sequences (without generate a mismatch), then the 
Levenshtein distance decreases. 
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The probability to have such distance reduction is given by: 
 
𝑃𝑑𝑒𝑐 = 13𝑑𝑛 𝜇(1 − 𝜇)𝑛−1 + 14 (𝑚 − 𝑛)𝑛 𝜆(1 − 𝜆)𝑛−1 + (𝑚 − 𝑛)𝑚 𝜆(1 − 𝜆)𝑚−1 
 
However, substitutions can occur in any of other similar nucleotides or one of d 
different nucleotides can mutate to either of two other nucleotides which do not 
exist in either of sequences; analogously, indel events can extend k length of 
existing gaps, create a new one or insert in shorter sequences one of three other 
nucleotides which are not present in the longest, then the Levenshtein distance 
increases with probability defined as: 
 
𝑃𝑖𝑛𝑐 =  𝜇(1 − 𝜇)𝑛−1 �𝑛 − 𝑑𝑛 +  23 𝑑𝑛� + 
 + 𝜆(1 − 𝜆)𝑛−1 �34 (𝑚 − 𝑛)𝑛 + 𝑛 − (𝑚 − 𝑛)𝑛 + 1� + 
 + 𝑛
𝑚
𝜆(1 − 𝜆)𝑚−1 
 
From these equations we can infer that probability of decrease is smaller than 
increase distance, therefore the distribution of probability is not symmetric 
around the initial Levenshtein distance. 
The higher is this difference, the relatively closer are starting sequences, 
provided that the mutation rate is sufficiently low and assuming it occurs 
randomly along the sequences. 
If the Levenshtein distance between two starting sequences exceeds the upper 
limit of the finite interval I = [x, x + dx] where the probability density function 
of the number of mutations assumes non-zero values, such that 
𝑃 �𝑙ev𝑎,𝑏(|a|, |b|) ∈ 𝐼� = ∫ 𝑝 �𝑙𝑒𝑣𝑎,𝑏(|a|, |b|)�dx𝑥+𝑑𝑥𝑥  = 0, then we could use 
the Bayesian maximum a posteriori estimate that maximizes, given the data, 
the probability that changes in Levenshtein distance occur because of errors 
during PCR and/or sequencing base calling, consequently re-integrating multi-
mapping reads into sequencing analysis. 
Assume series of random variables  X = [x1,…xR] of R elements, with a p(X; θ) 
distribution, and θ = [θ1,… θR] as the vector of parameters from which 
distribution depends. Let x1,…xn be N observations extracted from such 
distribution. 
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Posterior probability is given by: 
 
𝑃(𝜃|𝑋) =  𝑃(𝑋|𝜃)𝑃(𝜃)
𝑃(𝑋)  
 
where P(θ) is the probability a priori of θ parameter and P(X| θ) is the 
likelihood function, which is the probability of the observations given the 
parameters. If we considers x1,…xn observations the edit distance of reads from 
reference sequences and θ the mutation rate that generate this distance, we can 
maximize estimation of parameter θ, omitting P(X) that do not depend on it: 
  
𝜃𝑀𝐴𝑃 = arg max
𝜃
𝑃(𝑋|𝜃)𝑃(𝜃) 
 
Since we have not enough information to approximate P(θ), we can assume it 
as constant, so that maximum a posteriori probability and likelihood coincide, 
allowing us to resolve estimation of parameter by finding the value that 
maximize the likelihood. 
 
𝜃𝑀𝐿 = arg max
𝜃
𝑃(𝑋|𝜃) 
 
This expression represents the maximum likelihood, whereas binomial 
distribution was the probabilistic model we approached to calculate the 
probability that multi-mapping reads deriving from a specific DUX4 locus 
rather than another. Maximum likelihood estimate with Bernoulli model 
(binomial) is given by: 
 
𝐿(𝑋|𝜃) =  �𝑛𝑥�  𝜃𝑥(1 −  𝜃)𝑛−𝑥 
 
𝑙𝑛𝐿(𝑋|𝜃) = ln ��𝑛𝑥�� + 𝑥𝑙𝑛[𝜃] + (𝑛 − 𝑥)ln [1 −  𝜃] 
 
We use logarithmic formula to build log-likelihood curve along the values of θ 
between 0 and 1. The point of maximum of log-likelihood curve coincide with 
the value of θ that maximizes the likelihood of making the observations given 
the parameters. 
Since the range of values of θ around its point of maximum follow a Χ2 
distribution with a confidence level of 1 – α, mapping of reads can be resolved 
by performing log-likelihood ratio-based hypothesis test, where the probability 
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that a given read derive from two different loci is p = 0,5 represents the null 
hypothesis. 
𝐺 = 2 ln �𝐿(𝑌𝑚𝑎𝑥|𝑋)
𝐿(𝑌0,5|𝑋) �  
 
If log-likelihood ratio G > 𝛸1,0.052  then we refused null hypothesis and assume 
that a given read originated from specific DUX4 locus with a p-value ≥ 0,05 
despite of errors introduced by PCR and/or sequencing base calling. 
 
By preliminary alignment report, although < 5% was not specific amplification 
products, approximately 75% of DUX4 antisense sequences resulted multi-
mapping reads. Re-alignment was then performed by using BWA-MEM 
algorithm and multi-mapping sequences were evaluated by log-likelihood ratio 
test to exclude suboptimal alignments. By using above-explained statistical 
method, over 55% were assigned to specific DUX4 locus. Alignment results 
for each sample were indexed, merged into a unique bam files e visualized by 
IGV (Integrative Genome Viewer) software. 
Through MUSCLE algorithm, univocally mapped overlapping sequence data 
allowed us to easily generate consensus of three antisense transcripts deriving 
from D4Z4 (and/or 10q26 homologous cluster), DUX4L17 (DUXY3 on 
chromosome Y) and DUX4L26 (on chromosome 3), as shown in figure 14. 
We derived also a partial contig from multiple alignment of reads mapping to 
DUX4L9 (DUX4c), but we have not further investigated the existence of 
antisense transcripts from this locus. Moreover, comparison between data 
obtained from the different samples did not show differences at qualitative 
level, therefore both control and FSHD skeletal muscle cells would seem to 
express same transcripts. Interestingly, we found that DUX4-AS2 overcomes 
of ~75 nt the antisense transcript reported by Snider and colleagues. 
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3.2.5 Strand-specific RT-PCR corroborates existence of three 
antisense transcripts from chromosome 3, 4 and Y 
 
In order to validate consensus sequences and amplify one by one the antisense 
transcripts deriving from chromosome 3, 4 and Y, we designed three specific 
primers (figure XX) and performed three separated one-step strand-specific 
RT-PCR (ssRT-PCR) experiments, testing oligo specificity on total RNA 
extracted from Chinese Hamster Ovary (CHO) cell hybrids, each containing 
fragments of one of the above human chromosomes. 
A brief summary of human/CHO hybrids used in this study, including their 
evaluation by in situ hybridization, is reported in Material and Methods. One-
step ssRT-PCR experiments were performed after treatment with AZA/TSA, 
and followed by nested PCR, as described in detail (see Material and Methods). 
Total RNA of untreated hybrids was used as negative control. 
As displayed on agarose gel (Fig. 15A), DUX4-AS2 amplification product in 
CHO/Chr4 (RH4L319) cell line was obtained after RT with L4 oligo only; 
similarly L17 and L26 primers guaranteed specific amplification in CHO/Chr3 
(HYE7) and CHO/ChrY (HY94BT1) cell hybrids respectively. 
After testing ssRT primers, we performed the same reactions on human FSHD 
myotube (cohort 01, strain 157A) total RNA, using a neuroblastoma cell line 
(SH-SY5Y) as negative control (Fig. 15B). 
 
 
 
Fig. 15 - A) Nested PCR on total RNA extracted from 
somatic cell hybrids containing 4q35 (RH4L319), 3p12.3 
(HYE7) and Yp11.21 (HY94BT1). Retrotranscription was 
performed with primer specific to sequences deriving from 
chromosomes 4 (L4), 3 (L26) and Y (L17). NT = not treated 
with AZA/TSA; RT- = without RT enzyme; B = without 
ssRT primer. B) Nested PCR on total RNA extracted from 
FSHD myotubes (strain 157) after 7 days of differentiation 
(7 dd), retrotranscribed with L4, L17 and L26 ssRT primers. 
SH-SY5Y was used as negative control. 
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All nested PCR products from human FSHD myotubes were sub-cloned in TA 
cloning vector and then sequenced. As reported in following table, sequencing 
confirms specificity of retrotranscription reaction, validating transcripts found 
by analysis of 3’RACE products. 
 
 
 
According to guidelines defined by HGNC, antisense transcripts deriving from 
chromosomes 3 and Y, since they are the first to be identified in these loci, 
unlike transcript from 4q35.2, will be named DUX4L26-AS and DUXY3-AS, 
respectively. 
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3.2.6 Antisense transcript expression profiling during muscle 
differentiation highlights putative role of DUX4-AS2 in FSHD 
 
At first we focused our investigation on expression level of these antisense 
RNAs in order to identify differences between FSHD and related healthy 
control. We then compared affected (cohort 01, cell strain 157A) and control 
(cohort 01, cell strain 160U) bicep-derived immortalized muscle cell lines 
before to trigger (proliferating myoblasts) and at the end of differentiation 
process (myotubes differentiated to 7 days). However, no significant difference 
was found either among affected and healthy samples or between myoblasts 
and myotubes (not shown). 
Basing on the assumption that FSHD phenotype may be characterized by 
alterations of early stages of skeletal myogenesis, as previously observed, we 
wondered whether changes in expression of these antisense RNAs may occur 
during myotube formation. 
 
 
 
Fig. 16 - Analysis of DUX4-AS2, DUX4L27-AS and DUXY3-AS expression levels by qRT-
PCR, during early stages of differentiation, in biceps control and FSHD muscle cells. 
Expression values are normalized against expression level of control at time 0. Error bars 
indicate standard deviation. N = 3; * p-value < 0.05; ** p-value < 0.01.  
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Therefore, we chose to set up a time course, quantifying antisense RNAs at 
earlier stages of differentiation (from 0 to 4 days in KOSR-added medium) and 
extending the analysis to immortalized cell lines deriving from deltoids (cohort 
01, cell strains 172A and 175U), which, by clinical evaluation, was reported to 
be less affected than biceps. 
The extensive comparison of qRT-PCR results is shown in figures 16 and 17. 
In confirmation of our hypothesis, in FSHD biceps, DUX4-AS2 increases at 
early stages (0-2 days) of muscle differentiation, compared to controls (Fig. 
16A), showing to be much more expressed than its homologs too (Fig. 16B). 
On the other hand, in control samples, during early differentiation steps, we 
noticed that DUXY3-AS and DUX4L26-AS are generally higher than in FSHD 
(Fig. 16A). Interestingly, no difference between the three antisense RNAs was 
found in healthy biceps (except at T0) (Fig. 16B) and in affected deltoids (not 
shown), whereas in control deltoids this balance is biased towards DUXY3-AS 
(data not shown). 
 
 
 
Fig. 17 - Comparison of DUX4-AS2 expression levels by qRT-PCR between biceps and  
deltoid muscle cells, during early stages of control and FSHD differentiation. Expression 
values are normalized against expression level of control at time 0. Error bars indicate standard 
deviation. N = 3; * p-value < 0.05; ** p-value < 0.01.  
 
In further agreement whit our suppositions, preliminary evidence for putative 
involvement of DUX4-AS2 in early stages of muscle differentiation can be 
found by comparison of its expression level between biceps and deltoids, as 
shown in figure 17. Indeed, since biceps is part of most involved musculature 
in affected patients, in the first days of muscle differentiation of the bicep-
derived FSHD myoblasts, level of DUX4-AS2 significantly increases of more 
than 2 orders of magnitude when compared to deltoid. 
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3.2.7 DUX4-AS2 is localized into the nucleus, where interacts 
with DROSHA/DGCR8 complex 
 
In light of results obtained from evaluation of expression profile during early 
differentiation, functional studies have been focused on DUX4-AS2. At state of 
art, we have strong evidence of stable transcription and translation from DUX4 
gene inside D4Z4 macrosatellite (as well as DUX4c), but no suggestion about 
activity of widespread DUX4-like genes on other chromosomes. Hypothesizing 
that DUX4 gene may be affected by its antisense transcript, we assayed effects 
of DUX4-AS2 overexpression on DUX4 gene regulation. 
 
 
 
Fig. 18 - Evaluation of DUX4 mRNA and protein levels after transfection (T) of DUX4-AS2 in 
FSHD myoblasts. The increase of DUX4-AS2 concentration after transfection was assayed by 
qRT-PCR as well. Values correspond to relative expression against non-transfected cells (NT). 
GAPDH was used as normalizer. Error bars indicate standard deviation. N = 3; ** p-value < 
0.01.  
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We chosen to transfect DUX4-AS2 RNA as complete as possible, on the basis 
of the current characterization, then starting in vitro transcription from 5’ as 
reported by Snider and colleagues, to 3’ end found by 3’RACE, making a 
transcript of 554 nt in length. Transfection was performed on FSHD myoblasts 
and after 48 hours cells were collected to evaluate DUX4 mRNA and protein 
levels. No differences were found between transfected and non-transfected 
cells (Fig. 18). 
Several mi/siRNA-sized fragments have been reported within D4Z4 (Snider et 
al, 2009; Benhamed et al, 2012; Ameyar-Zazoua et al, 2012) and DUX4-AS2 
overlaps some of these short RNAs. Therefore, as alternative hypothesis, we 
inferred that this antisense transcript could be involved in the RNAi machinery, 
in particular as primary miRNA precursor. 
 
 
 
Fig. 19 - A) Subcellular localization of DUX4-AS2 in control and FSHD muscle cells. Cyto = 
cytoplasm; nuc.sol. = nucleoplasm; chro = chromatin-associated. Error bars indicate standard 
deviation. N = 5. B) Results of interaction assay between DGCR8 and biotinylated DUX4-AS2 
RNA. Its complementary RNA (sense strand) was used as scramble control. 
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To corroborate this supposition, we evaluated both subcellular localization of 
DUX4-AS2 in muscle cells and DGCR8 binding affinity by RNA-protein 
interaction assays. Interestingly, DUX4-AS2 is recognized by DGCR8 in vitro 
and appears to be significantly localized into the nucleus, but not associated to 
chromatin (Fig. 19).  
Taking advantage of these evidences, we deepened the role of DUX4-AS2 as 
miRNA precursor by computational methods, defining its secondary structures 
and thermodynamic properties, in order to predict all miRNAs that it might 
generate. 
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3.2.8 Secondary structure and predictive analysis report several 
miRNAs originating from DUX4-AS2 
 
The pipeline of method we implemented to predict miRNAs is based on use of 
previously reported and well-documented PriMir and Mirident algorithms (He 
et al, 2008; Liu et al, 2012). 
DUX4-AS2 sequence (554 nt) was processed to generate ~2800 overlapping 
subsequences ranging in length from 60 to 110 nt, thus according to length 
distribution of miRNA precursors (Krol et al, 2004; Fang et al, 2013). Each 
subsequence was folded by RNAfold (Vienna Package), obtaining information 
on intra-molecular interactions and minimum free energy (MFE). In order to 
predict pre-miRNA stem-loop structures, folded subsequences were screened 
by score matrix based on eleven features: base pairing of flanking bases, bulge 
length of pre-miRNA, base pairing of pre-miRNA, length of terminal loop, 
distance from terminal loop, initial bias of miRNA, base pairing of miRNA, 
MFE of pre-miRNA, length of pre-miRNA, GC content of pre-miRNA and GC 
content of miRNA. 
All miRNA-encoding candidates with a positive total score (PriMir score ≥ 0) 
were analyzed by using support vector machine (SVM)-based linear classifier 
(Mirident), which integrates sequence-structure motif information to accurately 
distinguish pre-miRNA from other stem-loop structures. To perform a correct 
classification, the algorithm was initially instructed with two training sets 
containing 484 human pre-miRNAs and 484 human non-pre-miRNA stem-loop 
structures, respectively. 
We finally predicted a total of 7 pre-miRNA candidates and, consequently, 16 
putative miRNAs originating from DUX4-AS2. Structural configuration and 
thermodynamic details of pre-miRNAs are reported in figure 20, followed by 
the list of all putative miRNAs. For one pre-miRNA (as-pre-miR-256/362), in 
particular, sequence bias of predicted cleavage by both DROSHA and DICER 
admits generation of two couple of iso-miRs: as-miR-276-5p/as-miR-279-5p 
and as-miR-316-3p/as-miR-320-3p. 
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Fig. 20 - Secondary structure of 
pre-miRNAs, flanked by mountain 
plot and entropy chart. Bases of 
structures were colored from blue 
to red according to increasing level 
of stability.  
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3.2.9 Six D4Z4-derived miRNAs are expressed in FSHD and/or 
healthy control muscle cells 
 
Validation of predicted miRNAs was performed by using LNA oligonucleotide 
made by Exiqon Synthesis Service and its proprietary primer design software. 
Experiments of qRT-PCR were set up with miRCURY  LNA system (Exiqon) 
on small RNA-enriched fractions, extracted from biceps control and FSHD 
myoblasts and myotubes (4-6 days of differentiation). 
 
 
 
Fig. 21 - Agarose gel electrophoresis of D4Z4-derived miRNAs detected by mercury LNA 
system in control cells (4 days of differentiation). The housekeeping  miR-103a was used as 
positive control. Amplicon lengths were in accord to those predicted by Exiqon. 
 
 
 
 
Fig. 22 - Evaluation of miRNA expression levels after transfection of DUX4-AS2 in healthy 
myoblasts versus control scramble. The miR-103a was used as normalizer. Error bars indicate 
standard deviation. N = 3. 
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Amplification products were visualized on agarose gel (Fig. 21) after their 
evaluation by melting curve analysis. We correctly amplified 6 of 16 predicted 
miRNAs in at least one of used samples. Moreover, to confirm miRNA 
derivation from DUX4-AS2, effects of its transfection were assayed on control 
myoblasts. As we expected, all detected miRNAs significantly increase their 
amount after DUX4-AS2 transfection, versus scramble control transfected cells 
(Fig. 22). 
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3.2.10 Validated miRNAs are differentially expressed during 
FSHD myogenesis, when compared to control 
 
The expression of 6 validated miRNAs was analyzed as well as their primary 
precursor, in biceps control and FSHD during different stages of differentiation 
(from 0 to 4 days in KOSR-added medium). 
 
 
Fig. 23 - Analysis of D4Z4-derived miRNA expression by qRT-PCR, during early stages of 
differentiation in biceps control and FSHD muscle cells. Values correspond to fold change over 
expression level of control at time 0. The miR-103a was used as normalizer. Error bars indicate 
standard deviation. N = 3; * p-value < 0.05; ** p-value < 0.01.  
 
Both as-miR-128-5p and as-miR-178-5p are preferentially expressed in control 
myoblasts and increase during differentiation. Conversely, as-miR-276-5p and 
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as-miR-320-3p are significantly expressed in affected cells, particularly after 2 
days of differentiation. On the other hand, as-miR-208-3p and as-miR-242-3p 
show a monotonic trend in FSHD cells, which assist to a slight increase of as-
miR-242-3p after 4 days only. In healthy muscle cells, instead, as-miR-242-3p 
remains constant during entire differentiation, whereas as-miR-208-3p shown a 
peak of expression at 2 days only (Fig. 23). 
Overall, comparison of relative expression levels of all miRNAs reveals that 
as-miR-276-5p, both in control and FSHD, and as-miR-320-3p, particularly in 
FSHD, are over 5-8 orders of magnitude more expressed than the others (Fig. 
24). For this reason, predictive analysis for gene target was initially conducted 
in relation to these two DUX4-AS2-derived miRNAs. 
 
 
Fig. 24 - Comparison of D4Z4-derived miRNA relative expression levels by qRT-PCR during 
early stages of biceps control and FSHD differentiation. The miR-103a was used as normalizer. 
Error bars indicate standard deviation. N = 3.   
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3.2.11 Target prediction suggests involvement of as-miR-276-5p 
and as-miR-320-3p in myoblast fusion and early differentiation 
 
To further understand the physiopathological functions concerning muscle 
differentiation of newly identified D4Z4-derived microRNAs, we oriented 
predictive analysis to guarantee accurate recognition of target genes involved 
in signaling pathways playing a pivotal role in orchestrating myoblast fusion 
and myofiber maturation processes, which we have thoroughly observed to be 
affected in FSHD. 
Several pathways that could influence normal skeletal muscle development and 
differentiation have been described to be significantly deregulated in FSHD 
versus normal myoblasts and myotubes: MAPK signaling pathway (Dip et al, 
2015), apoptosis (Kowaljow et al, 2007), oxidative phosphorylation (Turki et 
al, 2012), regulation of actin cytoskeleton (Dmitriev et al, 2011b; Rahimov et 
al, 2012; Tassin et al, 2012, Dib et al, 2015), calcium signaling pathway 
(Rahimov et al, 2012; Dib et al, 2015), RNA transport, RNA degradation (Dib 
et al, 2015) and VEGF signaling pathway (Osborne et al, 2007; Dib et al, 
2015). Other dysregulated signaling networks in FSHD are the same involved 
in hypertrophic cardiomyopathy (Tsuji et al, 2009) and cancer (Dmitriev et al, 
2014) too. 
Focusing on as-miR-276-5p and as-miR-320-3p, we identified miRNA target 
sites against 3’UTR, 5’UTR and coding regions (CDS) using a combination of 
TargetScan, miRanda and PITA algorithms with default parameters. Moreover, 
thermodynamic stability of miRNA-mRNA interactions and site accessibility 
against 3’UTR and 5’UTR/CDS were evaluated using RNAHybrid and RNA22 
prediction tools respectively (see Materials and Methods). We also cross the 
data with miRmap software results, for a more accurate assessment of bond 
energy and miRNA repression strength. 
Among annotated mRNA transcripts (derived from GenBank database Release 
167 and UniGene database Release 217) we found a total of 1535 and 299 
putative targets for as-miR-276-5p and as-miR-320-3p respectively. All 
predicted target genes were then analyzed through Gene Ontology (GO) and 
KEGG (Release 53.0) databases. 
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Fig. 25 - Gene ontology results for 1535 target genes of as-miR-276-5p. GO terms in the 
graphics are ordered from left to right according to their fold enrichment (from highest to 
lowest). 
 
The GO terms enrichment analysis of the targets of as-miR-276-5p (Fig. 25) 
showed that among the biological processes (BP) annotated, a relatively high 
percentage of these were involved in signal transduction (9,5%) and positive 
regulation of transcription from RNA polymerase II promoter (8,6%) and 
GTPase activity (6%). Most represented cellular components (CC) were 
cytoplasm (33%) and plasma membrane (26,8%), whereas protein binding 
(42,7%) was the mainly enriched molecular function (MF) involving predicted 
as-miR-276-5p targets. 
Analogously, as-miR-320-3p target gene analysis by GO revealed that signal 
transduction (10,8%) and positive regulation of transcription (9,1-6,1%) were 
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the BP terms most enriched, as well as protein binding (40,9%) in the MF 
annotation. On the other hand, as-miR-320-3p targets showed to be mainly 
localized and equally distributed between cytoplasm (34,1%) and nucleus 
(33,4%) (Fig. 26). 
 
Fig. 26 - Gene ontology results for 299 target genes of as-miR-320-3p. GO terms in the 
graphics are ordered from left to right according to their fold enrichment (from highest to 
lowest). 
 
KEGG pathways analysis revealed that approximately 22% of as-miR-276-5p 
targets fall within the signaling networks driving muscle differentiation and 
homeostasis, such as MAPK signaling pathway (86 genes), regulation of actin 
cytoskeleton (76 genes), TGF-beta, calcium and insulin signaling pathways 
(61, 58 and 57 genes respectively), focal adhesion (56 genes) and WNT, PI3K-
AKT and mTOR signaling pathways (45, 37 and 24 genes respectively). 
Myogenesis-related target genes of as-miR-320-3p were ~26% instead. Among 
them we found significantly enriched (FDR < 7,3 ∙ 10-9) the MAPK, WNT and 
mTOR signaling pathways (19, 16 and 11 genes respectively). Others were 
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also committed to PI3K-AKT, insulin and FoxO signaling pathways (16, 11 
and 10 genes respectively), or to regulation of actin cytoskeleton (13 genes). 
Notably, more than 10% of total genes targeted by both as-miR-276-5p and as-
miR-320-3p were annotated in KEGG pathways as cancer-associated. 
 
 
 
 
Fig. 27 - KEGG pathway enrichment results of muscle-related target genes of as-miR-276-5p 
and as-miR-320-3p. Pathways in the graphics are ordered from left to right according to their 
false discovery rate (FDR) values (from lowest to highest). 
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3.2.12 Overexpression of as-miR-276-5p and as-miR-320-3p 
affects members of mTOR signaling pathway 
 
Interestingly, all myogenesis-associated pathways targeted by both as-miR-
276-5p and as-miR-320-3p result strongly associated among them, whereas 
mTOR represents the crossroad between the upstream signaling mediated by 
MAPK, AMPK, WNT, RAS/ERK and IGF-1/PI3K/AKT, and the downstream 
effectors involved in cell growth and differentiation, in regulation of actin 
cytoskeleton, focal adhesion and VEGF signaling networks. Furthermore, 
mTOR complexes cross-talk with WNT and FoxO pathways in regulation of 
cell cycle and proliferation, contributing together with atrogin/MAFbx and 
MuFR-1 (activated by FoxO following insulin resistance), and the calmodulin-
dependent kinases signaling cascade in the control of muscle hypertrophy. 
We found that within mTOR signaling pathways, several members, such as 
RAPTOR, GβL, TSC1, TSC2, AKT2 and S6K1, are putative targets of both as-
miR-276-5p and as-miR-320-3p; moreover, as-miR-320-3p was predicted to 
potentially regulate also myostatin and SMAD3. 
Before testing effects of overexpression of both miRNAs, we decided to assay 
their putative targets involved in mTOR activity, in basal conditions, during 
early stages of differentiation, in control and FSHD muscle cells. 
 
 
 
Fig. 28 - Expression of mTOR pathway genes in FSHD proliferating myoblasts and after two 
days of differentiation, compared to healthy control. GAPDH was used as normalizer. Error 
bars indicate standard deviation. N = 3; * p-value < 0.05; ** p-value < 0.01. 
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At two days of differentiation in KOSR-added medium, TSC1, RAPTOR, GβL 
and myostatin show to be significantly deregulated in FSHD cells compared to 
controls. Interestingly, deregulation of these genes occurs at the same time that 
the two D4Z4-derived miRNAs are up-regulated, in FSHD. We also observed 
AKT2 slightly down-regulated in FSHD myoblasts (T0), but equally expressed 
after beginning of differentiation. On the contrary, RICTOR, which play a 
critical role during myoblast fusion by mTORC2 signaling, was found up-
regulated in FSHD cells, after two days of differentiation (Fig. 28). 
 
 
 
Fig. 29 - A) Expression analysis by qRT-PCR and B) assessment of protein levels after 
transfection of as-miR-276-5p and as-miR-320-3p in healthy myoblasts. Values correspond to 
relative expression against non-transfected cells (NT). GAPDH was used as normalizer. Error 
bars indicate standard deviation. N = 3; * p-value < 0.05; ** p-value < 0.01. 
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Transfection of as-miR-276-5p and as-miR-320-3p confirms, albeit indirectly, 
their involvement in regulation of mTOR signaling pathway. 
Indeed, as-miR-276-5p significantly down-regulated mRNA levels of TSC1, 
RAPTOR, AKT2 and S6K1 (not altered under basal conditions), whereas, as-
miR-320-3p overexpression significantly reduced the expression of TSC1, GβL 
and myostatin, determining concurrently an increase of RICTOR mRNA levels 
(Fig. 29A). At protein level, instead, deregulation mediated by as-miR-276-5p 
affects TSC1 and RAPTOR, as expected, and GβL too. Moreover, as-miR-320-
3p significantly reduced TSC1 and myostatin, but not GβL protein levels. After 
transfection of both miRNAs, we observed a significant increase of MyoD, 
suggesting that negative regulation of such genes can rapidly shift equilibrium 
toward the myogenic differentiation program (Fig. 29B). 
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3.3 Structural and functional analysis of DUX4-fl 
 
 
Physiopathological mechanism of action of the DUX4-fl protein remain still 
controversial, even though appears increasingly evident its role in myogenic 
differentiation, strengthening the idea of a direct interplay between D4Z4 and 
muscle determination proteins. We then worked to deepen the implications of 
DUX4-fl expression during muscle differentiation and to discover its elective 
interactors. To this aim, we have started to define structure of DUX4-fl by 
computational methods in order to predict its functional behavior. 
 
 
3.3.1 Ab initio modeling of DUX4-fl protein 
 
Infer the tridimensional structure of a protein can aid to predict its functional 
behavior and interactors, guide experimental efforts to their validation, and 
assist drug design. Operationally, existing computational methods of prediction 
can produce a structural model by using either comparative procedures based 
on sequence homology to proteins with known structure (template-based 
modeling), or ab initio (or de novo) modeling, without comparison with 
existing data. 
 
 
 
Fig. 30 - Sequence of DUX4-fl protein. Underlined residues refer to double homeobox domain.  
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Fig. 31 - (top) Sequence homology-based conserved domains and (bottom) sequence clusters 
aligned to DUX4-fl. Vertical black lines separate domains predicted by Ginzu protocol. 
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Having to define the complete structure of DUX4-fl without information 
concerning its domain organization, except for N-terminus homeobox (HOX) 
domains, we preferred to start looking for regions that were homologous to 
experimentally determined structures, and at first, we used multiple sequence 
alignment (MSA)-based approach to infer putative domains. 
 
 
 
Fig. 32 - Secondary structure of DUX4-fl protein. H = helix; E = beta sheet; C = coils. 
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DUX4-fl protein sequence of 424 aa in length (Fig. 30), was used as input for 
MSA analysis. Despite of the search for sequence homology may appear as a 
waiver of the ab initio modeling, the identification of homology-based 
structural model, as described below, can be evenly used as a reference, or 
constrains, for de novo protocol, reducing the processing time. Specifically, the 
search for homology-based conserved domains within DUX4-fl protein was 
performed by using PSI-BLAST software. 
After three alignment iterative cycles against the NCBI non-redundant protein 
sequence databases, output sequences with highest score of significance were 
clustered according to level of homology, query covering and phylogenetic 
distance, by using CLANS software. 
MSA analysis confirms the well-documented two homeodomains at residues 
19-78 and 94-153. Furthermore, sequence clustering suggested the putative 
existence of other three C-terminal domains (Fig. 31), although without a 
strong correspondence with existing proteins. Homology in DUX4-fl residues 
from 79 to 419 were indeed found with low level of significance (E-value 
raging from 1.79 ∙ 107 to 7.01 ∙ 103) against the DNA polymerase III, subunits 
gamma and tau (different sub-alignments ranging between residues 79-416), 
the large tegument protein UL36 (residues 91-414), the alpha-ketoglutarase 
decarboxylase (residues 175-274) and the provisional DNA translocase Ftsk 
(residues 211-419). 
 
 
 
Fig. 33 - Residue probability to be intrinsically disordered, computed by different algorithms. 
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Secondary structure prediction analysis by PSIPRED and JPred4 confirmed 
helix-turn-helix motif in homeodomains, connected by short loop or beta-sheet 
regions (Fig. 32). Three alpha helices were also predicted in leucine-rich C-
terminus domain, whereas neither alpha helix trans-membrane nor coiled-coil 
motifs have been recognized by using TMHMM and COILS algorithms. 
Moreover, central domains (3rd and 4th) and the initial portion of last domain 
(5th) of DUX4-fl showed loop/coil organization and further investigation 
revealed that the protein might take an intrinsically disordered conformation. 
Indeed, relying solely on information deriving from secondary structure, both 
central and C-terminus domains have an high probability (0.6-0.9) to be 
disordered, although the degree of mobility of hot loops, as determined from C-
alpha temperature B-factors, does not exceed the threshold of significance in 
much of the aminoacidic sequence (Fig. 33). 
The possible confirmation of DUX4-fl as intrinsically disordered protein could 
have a major impact on the definition of its biological role and the degree of 
structural plasticity. Furthermore, low complexity regions (LCRs) found within 
DUX4-fl sequence can easily suggest which regions are particularly involved 
in protein-protein interaction. Indeed, LCRs-containing proteins have been 
shown to have more binding partners than proteins without LCRs (Coletta et al, 
2010). 
 
 
 
Fig. 34 - Tridimensional representation of best structural model of DUX4-fl. Colors highlight 
different functional domains: 1st and 2nd HOX domains (yellow and gold); 3rd (green) and 4th 
(blue) central domains; and 5th (red) C-terminal domain. 
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Data obtained from MSA analysis for conserved domains and information 
deriving from secondary structure prediction were used within a hierarchical 
screening performed by Ginzu protocol, in order to define precise start/end 
residue position of each putative domain. De novo modeling was then operated 
by Rosetta software, generating several decoys for each domain (~10.000), 
filtering out all of them having unlikely strand topologies and then clustering 
remaining decoys (~2.000) on C-alpha root-mean-square deviation (RMSD) 
over ungapped position. Finally, we selected five top ranked cluster centers to 
assemble five alternative models of whole protein. 
Choice of final model (Fig. 34) was made by evaluating its prediction quality 
on ProSA web-server. It displays z-score of longest structural superposition of 
each model on the plot containing z-scores of the proteins in current PDB 
database (derived from both NMR and X-ray experiments). The z-score of the 
best DUX4-fl model (-7.81) represents the likelihood of getting a similar length 
match between similarly sized proteins by chance (Fig. 35). 
 
Fig. 35 - Position of DUX4-fl structure (black point) on plot containing the z-score of proteins 
with known structure deposited in PDB database. 
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3.3.2 Conformational and functional evaluation of DUX4-fl C-
terminus domain reveals homology with ubiquitin-binding CUE 
domains 
 
The two homeodomains of DUX4 have been extensively studied in the last 
years, in relation to their DNA-binding sites and specificity (Geng et al, 2011; 
Young et al, 2013; Zhang et al, 2016), and recently is also emerging a role of 
HOX domains in both DUX4 sub-cellular localization (Corona et al, 2013) and 
protein-protein interaction (Ansseau et al, 2016). 
DUX4-s, which is considered to be the non-toxic isoform, is composed by 
homeodomains only, lacking the last three domains we found in full-length 
forms. Moreover, DUX4-fl differs from DUX4-fl2 by retention of the first 
intron, which we supposed be able to modify the structure and, consequently, 
the biological function of 5th domain. 
For these reasons, we chose to further investigate structural characteristics of 
C-terminus of DUX4-fl, in order to infer a functional role that may explain its 
mechanisms of action during healthy and FSHD skeletal muscle differentiation. 
Particularly, analysis has been initially addressed to 5th domain (111 residues), 
deepening its geometric parameters by evaluation of Ramachandran plot (Fig. 
36A), angle and bond length of the backbone, C-beta deviations and rotamers. 
Quality of 5th domain modeling was assayed by QMEAN, crossing geometric 
data with structural references and evaluating torsion angle potential in order to 
recognize if the model is close to its native structure (Fig 36B). Subsequently, 
through optimization of hydrogen bonds and all-atom energy minimization we 
were able to improve the model (RMSD: 0.111) (Fig. 37). 
Refined model were then aligned to 37.751 tridimensional structures in PDB 
database (v.Feb17-16 - 90% non-redundant) by using both flexible and rigid 
alignment models. Superposition of 5th domain after rigid alignment revealed 
its structural homology with both D-domain (score: 92.92; p-value > 0.001; 
identity: 5.88%; similarity: 23.53%; RMSD: 4.38) of F-box proteins, involved 
in protein degradation, and ubiquitin-binding CUE domain (score: 62.73; p-
value > 0.05; identity: 7.14%; similarity: 21.43%; RMSD: 3.55) (Fig. 38A).  
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Fig. 36 - A) Ramachandran plot of DUX4-fl C-terminal domain. 96.3% of residues are in 
favored regions (blue) and 100% of residues are in allowed regions (violet) B) Comparison 
between QMEAN score of DUX4-fl C-terminal domain and PDB structures (left); the multi-
parameter scores determining QMEAN value of DUX4-fl C-terminal domain model (right). 
 
Since FSHD-related expression of DUX4-fl has been observed to affect protein 
ubiquitination, altering proteostasis and inducing aggregation of ubiquitinated 
proteins (Homma et al, 2015), we focused on homology with CUE domain and 
tried to verify whether 5th domain of DUX4-fl was able to bind ubiquitin. 
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Fig. 37 - QMEAN scores of refined DUX4-fl C-terminal domain and PDB structures (left); the 
multi-parameter scores determining QMEAN value of refined model (right). 
 
Therefore, we performed multi-alignment with human CUE domain consensus 
sequences in order to recognize aminoacidic binding motif in the 5th domain of 
DUX4-fl. Interestingly, multi-alignment shows that DUX4-fl carries with well-
conserved di-leucine (LL), but lacks MFP ubiquitin-binding motif of CUE2 
proteins (Fig. 38B). 
 
 
 
Fig. 38 - A) Superposition of rigid structural alignment of DUX4-fl and CUE domain. Region 
of structural homology is highlighted in red. B) Multiple alignment between DUX4-fl C-
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terminal domain (DUX4d5) and ubiquitin-binding CUE domains. The conserved residues of 
interaction with ubiquitin are squared in red. 
 
Instead of MFP motif, DUX4-fl has PAP sequence, quite similar to LAP and 
MAP motifs found in CUE1 and CUE4, respectively. Alanine, in substitution 
of Phenylalanine, has been reported to reduce affinity with ubiquitin (Shih et 
al, 2003); conversely, despite of resulting helix instability, effects on binding 
affinity of Methionine- or Leucine-to-Proline (LAP –> PAP or MAP –> PAP) 
substitution in DUX4-fl should be deepened. 
After having investigated structural and sequence similarity between 5th 
domain of DUX4-fl and ubiquitin-binding CUE domains, we proceeded with 
protein-protein interaction prediction by searching protein-protein interfaces 
and evaluating docking energy and complex stability by molecular dynamic 
simulation. For these analyses we used both 4th and 5th domains, assembled 
together, in order to include in the protein-protein interaction process the 
effects on 5th domain of its proximal regions. Ubiquitin X-ray structure refined 
at 1.8 Å resolution was obtained from PDB database (Accession ID: 1UBQ). 
Prediction confirmed binding to this protein by Leu8/Ile44/Val70 patch with a 
free energy of bonding interface of -31.57 Kcal/mol (Fig. 39). 
 
 
 
Fig. 39 - Tridimensional representation of interaction between 4th (blue) / 5th (red) C-terminal 
domain of DUX4-fl and ubiquitin (pink). In yellow are reported both PAP and LL ubiquitin-
binding residues. Leu8/Ile44/Val70 hydrophobic patch is highlighted in green. 
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Molecular simulations of 4th/5th domains of DUX4-fl, both before and after 
interaction with ubiquitin, were performed by using “all-atom OPLS” and 
“GROMOS96 43a1” force field, respectively, in ion-added solvated system 
(spc216 model). 
 
 
 
Fig. 40 - RMSD trajectories of the backbone (C-alpha) of 4th/ 5th  C-terminal domain unbound 
(blue) and bound with ubiquitin (red) during simulation of 2 ns. 
 
Energy minimization, in order to relax protein structure, and equilibration of 
the system at the appropriate temperature (300 K) and pressure (1 bar) values, 
to ensure its proper density, were set up. Finally, molecular dynamics were 
started and data collected for 2 ns. 
Trajectory analysis corroborated interaction model and bond stability between 
C-terminus of DUX4-fl and ubiquitin (Fig. 40). Evaluation of fluctuation of the 
C-alpha residues of DUX4-fl 4th/5th domains explained high RMSD (0.4 nm) 
whose trajectories converge at the end of simulation. Indeed, free N-terminal of 
4th domain resulted highly unstable, as expected, whereas the entire backbone 
suffered fluctuation ranging from 1 to 2.5 Å (Fig. 41). 
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Fig. 41 - Average of backbone (C-alpha) fluctuations of residues of the 4th/ 5th  C-terminal 
domain bound with ubiquitin, during simulation of 2 ns.  
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3.3.3 DUX4-fl translocates into cytoplasm during early muscle 
differentiation and its silencing slows myoblast fusion rate 
 
Contrary to what we expected, immunofluorescence on FSHD and control cells 
revealed increasing cytoplasmic localization of DUX4-fl in fusing myoblasts 
and myotubes (Fig 42). These results are in agreement with a recent works on 
interaction between DUX4/DUX4c and several cytoplasmic proteins (Ansseau 
et al, 2016). Effectively, by comparison of DUX4-fl sequence with database for 
experimentally validated leucine-rich nuclear export signals (NESs)-containing 
proteins, we found two NESs within DUX4-fl: one (LAQAIGI58) inside first 
homeodomain; and the other (LPCGLLL374) located at the C-terminal domain.  
 
 
 
Fig. 42 - Subcellular localization of DUX4-fl (green) by immunofluorescence during FSHD 
and control differentiation. Desmin (T0) and MyoD (T2-4) are reported in red. Nuclei were 
stained with DAPI (blue). 
 
In order to understanding the role played by DUX4-fl during differentiation, 
we performed experiment of gene silencing, by transfection of siRNA against 
C-terminus of DUX4. 
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Fig. 43 - A) Phase contrast microscope images of FSHD and control myoblasts at day 2 (T2) of 
differentiation, after transfection with DUX4 siRNA at T0. B) DUX4-fl and muscle-specific 
markers evaluation by western blot after 2 days of differentiation of control and FSHD cells 
transfected at T0. C) Phase contrast microscope images of affected and control myoblasts, 
followed by both DUX4-fl and MF20 western blot analysis, at day 4 of differentiation, after 
transfection of DUX4 siRNA at T2. Error bars indicate standard deviation. N = 3; * p-value < 
0.05. 
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Interestingly, we found that transient knockdown of DUX4-fl, when occurring 
at the beginning of differentiation, slowed myoblast fusion rate in FSHD and 
control cells (Fig. 43A), as confirmed by evaluation of muscle-specific markers 
(Fig. 43B). Conversely, the suppression of DUX4-fl after precise time point 
(T2) did not affect differentiation extent in both cell systems (Fig. 43C). 
This experiment confirmed a role of DUX4-fl in early differentiation of healthy 
myoblasts as well. Besides, following DUX4-fl silencing at T0, we also 
appreciated reversion of aberrant phenotype occurring in FSHD. (Fig. 44). 
 
 
 
Fig. 44 - Immunofluorescence with antibodies against DUX4-fl (red) and MF20 (green) of 
FHSD cells, transfected with siRNA against DUX4-fl at T0, and evaluated dafter 2-4 days of 
differentiation. FSHD non-transfected cells (NT) was used as control.  Nuclei were stained 
with DAPI (blue). 
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3.3.4 DUX4-fl co-localizes with M-cadherins, resulting in their 
altered distribution along plasma membrane in FSHD cells 
 
As we revealed, FSHD myotubes display altered nuclei pattern, resulting from 
disorganized fusion events and inadequate myoblast polarization. We then 
hypothesized that alterations may affect surface proteins involved in focal 
adhesion and cell fusion. Among these, M-cadherins play a pivotal role in 
withdrawal of myoblasts, their fusion into myotubes and in nuclei organization 
(Zeschnigk et al, 1995). 
Assessment of M-cadherins distribution in FSHD and control cell lines showed 
their delocalization along cell membrane and a significant accumulation in 
affected myoblasts and myotubes. Furthermore, by co-immunofluorescence, 
we also observed co-localization of M-cadherins with DUX4-fl, in FSHD 
muscle cells, compared to healthy control (Fig. 45), suggesting that altered 
distribution and interaction with DUX4-fl may be directly correlate. 
 
 
 
Fig. 45 - Co-immunofluorescence of M-cadherin (violet) and DUX4-fl (green) in FSHD and 
control cells, during muscle differentiation. Co-localization areas are spotted in white. Nuclei 
were stained with DAPI (blue). 
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Chapter IV - Discussion 
 
 
 
Our work reports a further deepening on the transcriptional complexity of the 
D4Z4 macrosatellite, particularly focalized on the production of a long non-
coding antisense RNA (DUX4-AS2) acting as a primary miRNA (pri-miRNA). 
A previous study carried out by using a strand-specific RT-PCR approach, 
reported three sense and three antisense transcripts from D4Z4 repeats, in 
control and FSHD myoblasts and myotubes, as well as several different 
mi/siRNA-sized fragments from both coding sequence (CDS) and 5’/3’UTR of 
DUX4 gene, embedded within D4Z4 repeat. Moreover, these noncoding RNAs 
have been detected also in myoblasts obtained by MyoD-induced fibroblast 
trans-differentiation, but not in quiescent fibroblasts (Snider et al, 2009), 
suggesting the existence in D4Z4 macrosatellite of muscle-specific regulatory 
modules and highlighting a potential role of this region in myogenic 
determination program. 
All three antisense RNAs, as well as their sense counterparts, displayed region 
of discontinuity with the DUX4 gene, suggesting their different functional 
activity, and particularly one (which Snider referred to as transcript D), 
overlapping in head-to-head orientation the 5’ end of DUX4 gene, has been 
hypothesized may directly regulate sense gene expression (Lim et al, 2015). 
Furthermore, all these noncoding RNAs showed polymorphisms, suggesting 
that different D4Z4 repeats could be actively transcribed (Snider et al, 2009). 
This evidence introduces an additional element of variability, which results in a 
greater complexity at functional level. 
Our initial approach, based on 3’RACE and deep sequencing, focalized on one 
of these antisense transcripts (herein named DUX4-AS2 and corresponding to 
previously reported transcript D) confirmed and extended all these findings. 
Particularly, we derived that: 1) DUX4-AS2 RNA is effectively transcribed in 
both FSHD and control muscle cells; 2) it is not polyadenylated, showing a 
length slightly higher (~75 nt) than that previously reported; and 3) other 
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D4Z4-like loci, or at least those located on chromosomes 3p12.3 and Yq11.21, 
transcribe detectable amounts of an homologous antisense transcript. 
In addition, alignment of antisense transcripts deriving from different loci 
evidenced the occurrence of polymorphisms, hence allowing to conclude that 
different units, with variable efficiency, mainly those located at 4q35.2 and 
Yq11.21, can be transcribed. 
Within D4Z4 locus, asymmetric bidirectional transcription has been recently 
reported following to identification of a distal upstream TATA-less promoter  
to DUX4 ORF (Block et al, 2012). TATA-less promoters have been classified 
as a large class of promoters associated with CpG-island-enriched sequences 
(Sandelin et al, 2007), driving multiple dispersed transcription start sites 
(Carninci et al, 2006; Marbach-Bar et al, 2015). 
Analysis of CAGE and DNAse I hypersensitivity data in muscle cells, across 
DUX4 upstream region, revealed an enrichment close to the identified TATA-
less promoter. According to its nature, this TATA-less/GC-rich promoter could 
explain observed clusters of transcription start points along DUX4 gene, 
particularly supporting our evidences of alternative transcription initiation for 
DUX4-AS2. Indeed, we found by analysis of SRX084669 dataset an antisense 
transcript, overlapping DUX4-AS2 itself, but starting 68 bp upstream. Further 
investigation by 5’RACE experiments will allow to confirm the eventually 
existence of a bias in TSS of this antisense RNA. 
On the other hand, from literature, there are no evidences of transcriptional 
activity from DUX4-like genes of chromosomes 3 and Y, which are referred to 
as pseudogenes, and reported to be strongly heterochromatic and unexpressed. 
For that reason, our validation, by ssRT-PCR, of antisense transcripts deriving 
from these loci, represents a novelty in itself and opens up the question of 
possible transcription of gene counterpart and its impact at functional level.  
In order to infer their biological role, we evaluated expression levels of DUX4-
AS2, DUX4L26-AS and DUXY3-AS during muscle differentiation, in both 
bicep-deriving control and FSHD cells, confirming their involvement in early 
stages leading to myoblast fusion. Particularly, at 0-2 days of differentiation, 
DUX4-AS2 showed an expression level significant higher than DUX4L26-AS 
and DUXY3-AS, in FSHD cells. Conversely, DUX4L26-AS and DUXY3-AS 
was over-expressed in control, at 0-2 days, compared to affected cells. 
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More compelling than above evidences is the comparison between biceps and 
deltoid muscle, where we found, mainly in FSHD, that DUX4-AS2 is much 
more expressed in biceps than in less-affected deltoid. Since we have been 
observed, although not significantly, both an higher disorganization in myotube 
assembly and a faster fusion rate in biceps than deltoid, we conjectured that 
DUX4-AS2 may be involved in these processes. This suggestion was further 
endorsed by differential expression recorded between FSHD and control cells, 
where disparities in myoblast fusion were much more evident. 
Due to sequence organization of DUX4-AS2 within the D4Z4 repeats, showing 
an overlapping to both 5’ end and regulatory region of DUX4 gene, we initially 
postulated that antisense may affect DUX4 itself, through transcriptional 
activation, transcriptional repression or via chromatin modification (Ling et al, 
2016). We have shown that DUX4 expression increases during differentiation, 
following the same trend, at least for initial days, of its antisense counterpart. 
However, over-expression experiments of DUX4-AS2, in FSHD myoblasts, 
confirmed absence of effects on DUX4 gene expression, as its mRNA and 
protein levels remained unchanged after antisense transfection. 
Hypothesis that DUX4-AS2 may generate mi/siRNA-like fragments has been 
recently proposed yet (Lim et al, 2015). On the contrary to our results, Lim and 
colleagues presented evidences of DUX4 negative regulation mediated by 
antisense-derived siRNAs in a DICER/AGO2 dependent manner. 
Nevertheless, all their experiments mainly consisted in transient transfection of 
several exogenous small RNAs mimicking the putative endogenous siRNAs, 
but did not show proofs of their effective existence in muscle cells. 
Moreover, Lim and colleagues successfully tested repression strength against  
DUX4 of other D4Z4-derived cytoplasmic and/or chromatin/AGO2-associated 
short RNAs that are actively produced in WI38 primary human fibroblasts and 
HeLa cells (Benhamed et al, 2012; Ameyar-Zazoua et al, 2012).  
Previous studies have been shown that antisense transcripts and their deriving 
chromatin-associated AGO2-coupled small RNAs are involved in epigenetic 
repression of DXZ4 macrosatellite (Chadwick, 2008; Pohlers et al, 2014). 
Here we reported, instead, that DUX4-AS2 is localized into the nucleus, not 
chromatin-associated, and, as supported by results of RNA-protein interaction 
assay, undergoes to DGCR8/DROSHA processing to generate miRNAs. 
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On the other hand, unlike canonical miRNA precursors, we demonstrated that 
DUX4-AS2 is not-polyadenylated. However, a recent paper reported that most 
lncRNAs functioning as primary miRNA transcripts use a polyadenylation-
independent mechanism of Polymerase II transcription termination, mediated 
by the microprocessor complex (Dhir et al., 2015). 
By RNA secondary structure and stem-loop folding analysis, we predicted 16 
miRNAs and amplified 6 of them in FSHD and control muscle cells. We also 
confirmed miRNA source by transfection of DUX4-AS2. Indeed, its over-
expression markedly increase levels of all 6 miRNAs. 
As we expected, none of these short RNAs corresponded to those previously 
reported by Snider and colleagues. Conversely, one cytoplasmic and two 
chromatin-associated small RNAs found in HeLa cells (Ameyar-Zazoua et al, 
2012) showed to share sequence with predicted as-miR-11-5p, as-miR-68-3p 
and as-miR-242-3p. 
Among these, only as-miR-242-3p was found in affected and control muscle 
cells, whereas both as-miR-11-5p and as-miR-68-3p, originating from the same 
pre-miRNA, were not successfully amplified in muscle system. Interestingly, 
one of exogenous siRNA, which is able to suppress DUX4 expression (Lim et 
al, 2015), matches the sequence of as-miR-178-5p we detected in control cells 
only. 
Expression profiling of these miRNAs, moreover, highlighted quantitative and 
qualitative differences between FSHD and control cells, suggesting variability 
in processing activity and efficiency. Moreover, pri-miRNA conformational 
analysis showed that all precursor hairpins generating validated miRNAs can’t 
coexist within the same structure. 
Alternative DROSHA processing (Wu et al, 2009) and DROSHA/DICER 
cleavage shifting have been shown to produce miRNA end polymorphisms 
(Ruby et al, 2006; Seitz et al, 2008). Several pri-miRNAs have been reported to 
encode for subsets of clustered miRNAs (Liang et al, 2007), as well as has 
been recently observed the involvement of spliceosome complex in modulation 
of alternative biogenesis of several miRNAs, such as the splice-site-
overlapping miR-412 (Melamed et al, 2013). 
However, our findings represents a novelty, since we introduce a new level of 
alternative processing of pri-miRNA, depending on stabilization of a specific 
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subset of suboptimal structures. Indeed, two miRNA miRNAs (as-miR-128-5p 
and as-miR-178-5p) were detected only in control cells, whereas the others 
were expressed in both cell types, but showing a significant up-regulation in 
FSHD cells, during the early stages of differentiation. Particularly, as-miR-
276-5p and as-miR-320-3p, after 48 hours of differentiation, exhibited an 
increase of expression several order of magnitude, compared to other miRNAs. 
Furthermore, as-miR-11-5p and as-miR-68-3p are encoded in HeLa, but not in 
muscle cells, and as-miR-242-3p occurs in both cell type, following a miRNA-
like, in muscle cell, or a siRNA-like behaviour, in HeLa cell lines. 
All together, these data strongly suggest that the unbalance in expressing 
endogenous miRNAs deriving from the same primary precursor can be tissue-
specific and/or influenced by the pathophysiological status of the cell. 
As above mentioned, two of the identified D4Z4-derived miRNAs (as-miR-
276-5p and as-miR-320-3p) were found significantly up-regulated in FSHD 
cells during early stages of muscle differentiation. Defects in muscle 
differentiation of FSHD cells have been already reported  (Winokur et al, 2003; 
Barro et al, 2010; Dib et al, 2015), and also FSHD cells used in this study 
showed differentiation defects implying a premature formation of disorganized 
myotubes. In the attempt to define the possible involvement of dysregulated 
miRNAs into described FSHD differentiation anomalies, we focused our 
attention to putative gene targets involved in signaling pathways playing a 
major role in myoblast fusion and myofiber maturation processes. 
Our choice of investigating the effect of as-miR-276-5p and as-miR-320-3p on 
genes of the mTOR pathway was mainly based on several papers highlighting 
its central role in muscle differentiation and muscular dystrophy (Ge et al, 
2009; De Palma et al, 2012, 2014; Wilson et al, 2016). 
In particular, knockdown of RAPTOR, a member of mTORC1, was observed 
to enhance myoblasts differentiation (Jaafar et al, 2011; Ge et al, 2011; Wilson 
et al, 2016) whereas its over-expression suppressed myotubes formation (Ge et 
al, 2011). Negative effects of RAPTOR on muscle differentiation was proposed 
to be mediated by inhibition of RICTOR through S6K1 phosphorylation 
(Dibble et al, 2009; Julien et al, 2010; Jaafar et al, 2011). On the other hand, 
mTORC2 activates AKT (or protein kinase B), a critical regulator of skeletal 
myogenesis and muscle maintenance (Ge and Chen, 2012). Moreover, mTOR 
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signaling is involved in the finely regulation of both atrophic and hypertrophic 
stimuli. In this regard, TSC1/TSC2 complex, which is triggered by FoxO3 and 
myostatin/SMAD3 axis, controls atrophy program and its down-regulation 
results in enlarged myotubes (Kuleesha et al, 2016).  
Effectively, overexpression of as-mirR-276-5p and as-mir-320-3p in muscle 
cells reduced the expression of molecular markers controlling cell proliferation 
and atrophy (such as RAPTOR, TSC1 and myostatin), and enhanced RICTOR 
mRNA and MyoD protein levels, shifting the balance toward differentiation 
program, hence explaining the observed premature fusion of FSHD myoblasts 
into swelled myotubes. 
Anyway, further investigation will be necessary and experimental efforts will 
be oriented to validate target genes of as-mirR-276-5p and as-mir-320-3p, as 
well as of the other predicted miRNAs. 
On the other hand, an analogous pro-differentiation effect we also highlighted 
for the master gene of FSHD: DUX4. Indeed, According to recent findings 
(Ansseau et al, 2016), we found that DUX4-fl isoform is equally expressed in 
both affected and healthy myoblasts, increases during muscle differentiation 
and translocates into the cytoplasm, where it could be involved in focal 
adhesion and cell fusion signaling, particularly regulating the re-cycling of M-
cadherins. 
The choice between degradation and recycling can help fine-tune the amount 
of cadherin present at adherens junctions and the strength of cell-cell adhesion 
(Nanes and Kowalczyk, 2012). Moreover,  the fusion process mediated by the 
M-cadherin-β-catenin complex is tightly regulated and its persistence might 
have a dramatically negative effect on terminal myogenic differentiation 
(Kramerova et al, 2006). 
Degradation of M-cadherins is mediated by ubiquitination and proceeds in a 
proteasome-dependent manner. In our study we found  that M-cadherins are 
unevenly distributed along plasma membrane of FSHD cells, particularly in the 
first stages of muscle differentiation, where co-localizes with DUX4-fl. 
From predictive analysis on tertiary structure of DUX4-fl, we revealed that it 
may have characteristics of intrinsically disordered proteins (IDPs). Due to 
their structural plasticity, IDPs can interact with multiple proteins or interface 
with a single protein through distinct points of interaction (Van Roey et al, 
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2014; Habchi et al, 2014). These evidences, in particular, could explain results 
reported by Ansseau et colleagues about validation of a large group of very 
different DUX4 cytoplasmic interactors. 
Furthermore, several protein that regulate ubiquitination possess IDRs and, 
specifically, de-ubiquitinating enzyme USP36 uses them to scaffold multiple 
protein interaction sites (Reed et al, 2015). By structural alignment, we found 
homology between DUX4-fl C-terminal domain and ubiquitin-binding CUE 
domain, and we have computationally validated interaction with ubiquitin by 
molecular dynamics simulation. As previously mentioned, the involvement of 
DUX4-fl in ubiquitin pathway has been recently reported (Homma et al, 2015). 
For these reasons, and supported by these results, we firstly hypothesized that 
DUX4-fl may disrupt M-cadherins ubiquitin-mediated degradation signaling, 
enhancing in affected myoblasts the fusion process. 
We demonstrated that DUX4-fl silencing during first stages of differentiation 
slows fusion rate, driving to normal myotube formation. However, same effects 
on myogenic differentiation was observed in control cells, suggesting that 
DUX4-fl is similarly involved in muscle differentiation, but it behaves in a 
different, more controlled way. 
Certainly, these remain preliminary evidences and future aims will be orientate 
to confirm these observation and corroborate structural and interaction models 
we inferred. Nevertheless, all reported results represent an additional evidence 
of the transcriptional complexity of the D4Z4 genomic region and its possible 
impact on the pathophysiology of skeletal myogenesis. 
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